A Learning Health System Randomized Trial of Monoclonal Antibodies for Covid-19

Erin K. McCreary PharmD¹, J. Ryan Bariola MD¹, Tami Minnier MS², Richard J. Wadas MD³, Judith A. Shovel BSN², Debbie Albin BS⁴, Oscar C. Marroquin MD⁵, Kevin E. Kip PhD⁵, Kevin Collins MBA⁵, Mark Schmidhofer MD⁶, Mary Kay Wisniewski, MA², David A Nace MD⁷, Colleen Sullivan MHA^{8,11}, Meredith Axe BS³, Russell Meyer MBA³, Alexandra Weissman MD³, William Garrard PhD⁵, Octavia M. Peck-Palmer PhD⁹, Alan Wells MD DMSc⁹, Robert D. Bart MD^{10,13}, Anne Yang MD¹⁴, Lindsay Berry PhD¹⁵, Scott Berry PhD¹⁵, Amy Crawford PhD¹⁵, Anna McGlothin, PhD¹⁵, Tina Khadem PharmD¹¹, Kelsey Linstrum MS^{8,11}, Stephanie K. Montgomery MS^{8,11}, Daniel Ricketts MT⁸, Jason N. Kennedy MS^{8,13}, Caroline J. Pidro BS⁸, Ghady Haidar MD¹, Graham M. Snyder MD¹, Bryan J. McVerry, MD¹², Derek C. Angus MD, MPH^{8,11,13}, Paula L. Kip PhD², Christopher W. Seymour MD, MSc^{8,11,13}, David T. Huang MD, MPH^{3,8,13*}

AFFILIATIONS

- Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 2. Wolff Center, UPMC, Pittsburgh, PA, USA
- 3. Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 4. Supply Chain Management/HC Pharmacy, UPMC, Pittsburgh, PA, USA
- 5. Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 7. Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 8. Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center,
 Department of Critical Care Medicine, University of Pittsburgh School of Medicine,
 Pittsburgh, PA, US
- 9. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 10. Health Services Division, UPMC, Pittsburgh, PA, USA

- 11. Health System Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
- 12. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 13. Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 14. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 15. Berry Consultants, Austin, TX, USA

*CORRESPONDENCE

David T. Huang, MD, MPH

Professor, Critical Care Medicine, Emergency Medicine, Clinical and Translational Science

UPMC and University of Pittsburgh

606B Scaife Hall

Pittsburgh, PA 15213

huangdt@upmc.edu

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

ABSTRACT Background: Neutralizing monoclonal antibodies (mAb) targeting SARS-CoV-2 decrease hospitalization and death in patients with mild to moderate Covid-19. Yet, their clinical use is limited, and comparative effectiveness is unknown. **Methods:** We present the first results of an ongoing, learning health system adaptive platform trial to expand mAb treatment to all eligible patients and evaluate the comparative effectiveness of available mAbs. The trial launched March 10, 2021. Results are reported as of June 25, 2021 due to the U.S. federal decision to pause distribution of bamlanivimab-etesevimab; patient follow-up concluded on July 23, 2021. Patients referred for mAb who met Emergency Use Authorization criteria were provided a random mAb allocation of bamlanivimab, bamlanivimabetesevimab, or casirivimab-imdevimab with a therapeutic interchange policy. The primary outcome was hospital-free days (days alive and free of hospital) within 28 days, where patients who died were assigned -1 day. The primary analysis was a Bayesian cumulative logistic model of all patients treated at an infusion center or emergency department, adjusting for treatment location, age, sex, and time. Inferiority was defined as a 99% posterior probability of an odds ratio < 1. Equivalence was defined as a 95% posterior probability that the odds ratio is within a given bound. **Results**: Prior to trial launch, 3.1% (502) of 16,345 patients who were potentially eligible by an automated electronic health record (EHR) screen received mAb. During the trial period, 23.2% (1,201) of 5,173 EHR-screen eligible patients were treated, a 7.5-fold increase. After including

additional referred patients from outside the health system, a total of 1,935 study patients

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

received mAb therapy (128 bamlanivimab, 885 bamlanivimab-etesevimab, 922 casirivimabimdevimab). Mean age ranged from 55 to 57 years, half were female (range, 53% to 54%), and 17% were Black (range, 12% to 19%). Median hospital–free days were 28 (IOR, 28 to 28) for each mAb group. Hospitalization varied between groups (bamlanivimab, 12.5%; bamlanivimabetesevimab, 14.7%, casirivimab-imdevimab, 14.3%). Relative to casirivimab-imdevimab, the median adjusted odds ratios were 0.58 (95% credible interval (CI), 0.30 to 1.16) and 0.94 (95% CI, 0.72 to 1.24) for the bamlanivimab and bamlanivimab-etesevimab groups, respectively. These odds ratios yielded 91% and 94% probabilities of inferiority of bamlanivimab versus bamlanivimab-etesevimab and casirivimab-imdevimab respectively, and an 86% probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab, at the prespecified odds ratio bound of 0.25. Twenty-one infusion-related adverse events occurred in 0% (0/128), 1.4% (12/885), and 1.0% (9/922) of patients treated with bamlanivimab, bamlanivimabetesevimab, and casirivimab-imdevimab, respectively. **Conclusion:** In non-hospitalized patients with mild to moderate Covid-19, bamlanivimab, compared to bamlanivimab-etesevimab and casirivimab-imdevimab, resulted in 91% and 94% probabilities of inferiority with regards to odds of improvement in hospital-free days within 28 days. There was an 86% probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab at an odds ratio bound of 0.25. However, the trial was unblinded early due to federal distribution decisions, and no mAb met prespecified criteria for statistical inferiority or equivalence. (ClinicalTrials.gov, NCT04790786).

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

INTRODUCTION Neutralizing monoclonal antibodies (mAb) targeting SARS-CoV-2 were granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for treatment of mild to moderate Covid-19, and significantly decrease hospitalization and death in this patient population.¹⁻⁹ However, clinical use is limited due to lack of access, logistical challenges of administration, and incomplete clinician and patient awareness. ¹⁰ The comparative effectiveness of one mAb versus another is also unknown.¹¹ In February 2021, UPMC partnered with the U.S. Federal Covid-19 Response Team to expand clinical use to all EUA-eligible patients and evaluate the comparative effectiveness of the available mAbs using a learning health system approach. This approach embeds knowledge generation into daily practice to seek continuous improvement in care. 12,13 For all mAb-eligible patients treated at UPMC, we set two objectives, (i.) to equitably treat as broad of a proportion of mAb-eligible patients as possible, and (ii.) to compare effectiveness between mAbs overall and over time as SARS-CoV-2 variants emerged. This report presents the first results of the OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for Covid-19) trial.¹⁴

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

the EUA-governed mAb.⁷⁻⁹

METHODS Expansion of Monoclonal Antibody Access UPMC is an integrated network predominantly serving Western and Central Pennsylvania. Prior to U.S. federal partnership, UPMC developed a mAb treatment infrastructure in response to the bamlanivimab EUA issued November 9, 2020. The first patient was treated at a one of 18 outpatient infusion centers within this infrastructure on December 9, 2020. 15.16 After U.S. federal partnership, mAb infusion capacity was expanded to all emergency departments (ED, n = 31), infusion center staffing and hours were increased, and a multifaceted outreach campaign to patients and clinicians was launched. UPMC partnered with government public health bodies, community outreach leaders, and neighboring health systems to increase awareness and referrals, and a home infusion company to provide treatment for homebound patients (Chartwell Pennsylvania, Oakdale, PA). The UPMC Pharmacy and Therapeutics Committee developed a therapeutic interchange policy on November 21, 2020 in response to the issuance of an EUA for casirivimab-imdevimab. ⁹ The policy considered all available mAb equivalent; a patient could receive any mAb based on local inventory. The policy was updated to include bamlanivimab-etesevimab on February 9, 2021 and to remove bamlanivimab on March 31, 2021 due to U.S. federal decisions.^{8,17} All pharmacies supplying all infusion sites had equal opportunity to order any available mAb from a central supply facility. All mAb were ordered by prescribers as a generic referral order and provided as per FDA EUA guidance (Supplement). Prescribers were required to provide and review all mAb EUA Fact Sheets with the patient at time of referral and explain the patient could receive any of

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

Trial Design and Oversight OPTIMISE-C19 is an open-label, pragmatic, comparative effectiveness, platform trial with response-adaptive randomization. The three mAb (bamlanivimab, bamlanivimab-etesevimab, and casirivimab-imdevimab) evaluated in this report were supplied by the U.S. federal government. The trial was approved by the UPMC Quality Improvement Committee and launched March 10, 2021 (Project ID 3280). The University of Pittsburgh Institutional Review Board considered provision of mAb therapy quality improvement and only the additional data collection and analyses represented research (STUDY21020179). A custom application built into the electronic health record (EHR) linked local inventory to patient encounters and provided a random mAb allocation at the time of referral, within the therapeutic interchange policy. ¹⁸ Allocation was initially assigned equally to available mAb. Patients provided verbal consent to receive mAb therapy as part of routine care. The prescriber and/or patient could request a specific mAb if desired. **Patients** A centralized monoclonal antibody operations team confirmed patient eligibility upon referral. Patients were eligible for mAb if they met EUA criteria, which included patients with a positive SARS-CoV-2 polymerase chain reaction or antigen test, mild to moderate symptoms for 10 days or less, and risk factor(s) for progression to severe Covid-19. The EUA criteria excluded patients who required supplemental oxygen above baseline requirements, weighed < 40 kg, were < 12

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

years of age, or were hospitalized for Covid-19 (Supplement). Patients were screened in the ED or outpatient infusion centers. **Outcomes** To evaluate clinical mAb use expansion, we screened for potential eligibility based on EHR identification of all outpatients with a positive SARS-CoV-2 polymerase chain reaction or antigen test performed within the health system and an EUA-defined risk factor for progression to severe disease. Race was derived from registration system data using fixed categories consistent with the Centers for Medicare & Medicaid Services EHR meaningful use dataset and the AMA Manual of Style. 19,20 Pre-specified categories included non-Hispanic Black, non-Hispanic White, and Other. Individuals were considered Other due to small sample sizes for Hispanic, American Indian, and other races and ethnicities. Geographic distribution of mAb treatment was illustrated using zip code of patient residence. 21,22 To evaluate comparative effectiveness, the primary outcome was hospital-free days up to day 28 after mAb treatment. This outcome is an ordinal endpoint with death up to day 28 as the worst outcome (labeled -1), then the length of time alive and free of hospital, such that the best outcome would be 28 hospital-free days. If a patient had intervening days free of hospital and was then re-hospitalized, the patient was given credit for the intervening days as free of the hospital. Secondary outcomes included mortality at 28 days. We evaluated rates of hospitalization by infusion location, and incidence of adverse events (**Supplement**). We assessed SARS-CoV-2 variant prevalence in our Pennsylvania catchment over time using Global Initiative on Sharing All Influenza Data (GISAID) data.²³

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

Data Collection OPTIMISE-C19 was embedded in the EHR to access routine patient care data and was augmented by manual review and data collection. We ascertained the primary outcome of hospital-free days by linking inpatient (Cerner, Kansas City, Missouri) and outpatient (Epic, Madison, Wisconsin) EHRs, as shown in prior work. 18 We conducted patient-directed phone calls at day 28 to ascertain health care encounters outside our health system, and Social Security Administration Death Master File queries for vital status.²⁴ We collected adverse events in i.) a secure, electronic file sharing application completed by infusion center nurses on the day of mAb treatment, and ii.) an internal patient safety reporting system for adverse reactions completed by nursing and physician staff in infusion centers and EDs. Adverse event severity was adjudicated blinded to mAb type. **Statistical Analysis** To determine the epidemiology and equitability of mAb infusions in our region, we measured the proportion of EHR-screen eligible patients treated with any mAb stratified by demographics, geography, and prior to or after trial launch. Treatment "prior to the trial" was from December 9, 2020 until March 9, 2021, and "during the trial" from March 10 to June 25, 2021. To analyze comparative effectiveness, the trial statistical analysis plan was written by blinded investigators prior to data lock and analysis (Supplement) and applied to patients treated with mAb from March 10, 2021 to June 25, 2021. The platform is designed to continuously evaluate multiple mAb, with randomization continuing until pre-determined statistical thresholds are met.

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

The trial launched with equal allocation randomization and planned interim analyses for adaptive randomization where mAb performing better would be given higher randomization probabilities. The mAb arm at the first adaptive analysis with the largest sample size was specified as the referent arm, as there was no non-mAb control and all patients received active treatment. All mAb were compared to each other. The methods and results are reported in accordance with the CONSORT Pragmatic Extension checklist (**Supplement**). ²⁵ An unblinded statistical analysis committee conducted interim and final analyses with R version 4.0.5 using the RStan package version 2.21.0 (R Foundation, Vienna, Austria) and reported results to the UPMC Chief Medical Officer who functioned in a data and safety monitor role for the study. The primary analysis population was the "as-infused" population which consisted of patients randomly allocated mAb and subsequently treated. As all trial arms included mAb, there was no anticipated relationship between lack of infusion and the assigned arm. Baseline patient characteristics of those infused were compared to those allocated but not infused using mean (SD) or median (IQR) for continuous variables, and proportions for categorical variables. The primary analysis model was a Bayesian cumulative logistic model that adjusted for treatment location (infusion center or ED), age (<30, 30-39, 40-49, 50-59, 60-69, 70-79, and ≥80 years), sex, and time (2-week epochs). The comparison between individual mAbs were based on the relative odds ratio between a given two arms for the ordinal primary outcome. An odds ratio for an arm to a comparator greater than 1 implies improved outcomes on the ordinal scale. A sliding scale of equivalence was set according to odds ratio bounds of 0.25, 0.20, 0.15, 0.10, and 0.05. Equivalence between two arms was defined as a 95% posterior probability that the odds

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

ratio is within a given odds ratio bound. Inferiority of one arm compared to another was defined as a 99% posterior probability of an odds ratio less than 1. To determine potential differential treatment effects of mAbs by Covid-19 variant type, patients were categorized into four time epochs relative to variant prevalence in 2021 (March 10 - 31; April 1 – April 30; May 1 – 31; June 1 – 25). Treatment effects were measured from the primary model over time with hierarchical prior distributions. **Decision to publish interim results** The U.S. Department of Health and Human Services halted distribution of bamlanivimab alone on March 25, 2021, and of bamlanivimab-etesevimab on June 25, 2021, due to concern of lack of efficacy against certain SARS-CoV-2 variants that were predominant in the U.S. at those times. 26,27 As further treatment with these mAbs was not possible, we unblinded and analyzed patients allocated through June 25, 2021, with follow up completed by July 23, 2021. **RESULTS Expansion of monoclonal antibody treatment** Prior to the trial, 16,345 patients were EHR-screen eligible. Of these, 502 patients overall (3.1%) were treated with mAb, of whom the proportion of Black (2.6%) and White (3.1%) treated patients were similar. After trial launch, 1,201 of 5,173 EHR-screen eligible patients (23.2%) were treated. The proportion of eligible White patients receiving mAb increased from 3.1 to 21.6% and eligible Black patients receiving mAb increased from 2.6 to 29.9% during the trial. Broad geographic expansion was evident across the catchment (**Figure 1**).

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

Trial patients Between March 10 and June 25, 2021, 5,173 outpatients with a positive SARS-CoV-2 test within UPMC were EHR-screen eligible, of whom 1,382 were referred and underwent random mAb allocation. 1,084 EUA-eligible patients with a positive SARS-CoV-2 test from outside of UPMC were also referred, yielding a total of 2,466 patients who were assigned a random mAb allocation. Of these, 1,935 (78%) were infused and comprised the primary analysis cohort (bamlanivimab [n = 128], bamlanivimab-etesevimab [n = 885], casirivimab-imdevimab [n = 885]922], **Figure 2**). Of the 531 patients assigned a random mAb allocation and excluded from the primary analysis, most (n = 300, 56%) were not infused due to becoming clinically ineligible at time of infusion scheduling (n = 154, 29%) or patient declining treatment (n = 146, 27%). Eighty-eight patients (17%) received mAb at a location without available EHR data or while hospitalized for non-Covid-19 reasons. No patient or provider requested a specific mAb different than randomized assignment. Baseline characteristics were similar across groups (**Table 1**). The mean age for the three groups was 55 - 57 years, half were female (range, 53% - 54%), 18% were Black (range 12% - 19%), and the most common risk factors were advanced age, high body mass index, and hypertension. Of the 241 patients for whom vaccine status was known, 57 (24%) reported being unvaccinated, 120 (49%) partly vaccinated, and 64 (27%) fully vaccinated. Mean duration of symptom onset to referral was 5 (2.1) days.

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

Primary outcome The median hospital-free days were 28 (IQR, 28-28) for each mAb group (**Table 2**, **Figure 3**). Relative to the casirivimab-imdevimab group, the posterior median adjusted odds ratios from the primary model were 0.58 (95% credible interval, 0.30 to 1.16) and 0.94 (95% credible interval, 0.72 to 1.24) for the bamlanivimab and bamlanivimab-etesevimab groups, respectively. The probabilities of inferiority for bamlanivimab versus bamlanivimab-etesevimab and casirivimabimdevimab were 91% and 94% respectively. The probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab with a bound of 0.25 for the odds ratio was 86%. No comparison met prespecified criteria for statistical inferiority or equivalence. **Secondary outcomes** The 28-day mortality rates were 0.8% (1/128), 0.8% (7/885), and 0.7% (6/922) and hospitalization rates were 12.5% (16/128), 14.7% (130/885), and 14.3% (132/922), in the bamlanivimab, bamlanivimab-etesevimab, and casirivimab-imdevimab groups, respectively (**Table 2**). For patients receiving mAb in an outpatient infusion center, rates of hospitalization after treatment were 7.8% (bamlanivimab), 6.5% (bamlanivimab-etesevimab), and 6.9% (casirivimab-imdevimab). For patients receiving mAb in an ED, rates of hospitalization after treatment were 32% (bamlanivimab), 23.7% (bamlanivimab-etesevimab), and 21.7% (casirivimab-imdevimab). **Adverse events** Twenty-one infusion-related adverse events occurred in 0% (0/128), 1.4% (12/885), and 1.0% (9/922) of patients treated with bamlanivimab, bamlanivimab-etesevimab, and casirivimab-

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

imdevimab, respectively. Five events (0 bamlanivimab, 1 bamlanivimab-etesevimab, 4 casirivimab-imdevimab) were adjudicated as serious (Supplement). Differences in treatment over time During the trial the Alpha SARS-CoV-2 variant was the dominant variant of concern, while the Delta variant became more prevalent in the final time epoch (**Supplement**). We found no relative difference in mAb treatment effects over time and no comparisons reached a prespecified statistical threshold (**Supplement**). **DISCUSSION** In a learning healthcare system trial of mAb for Covid-19, treatment of EHR-screen eligible patients increased 7.5-fold, particularly among historically and geographically underserved populations. We found a 91% and 94% probability of inferiority of bamlanivimab respectively to bamlanivimab-etesevimab and casirivimab-imdevimab, and an 86% probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab at the first pre-specified bound, with regard to the odds of improvement in hospital-free days by 28 days. However, the bamlanivimab and bamlanivimab-etesevimab arms were stopped early, and the identified probabilities did not meet prespecified statistical triggers for trial conclusions of inferiority or equivalence. OPTIMISE-C19 is designed to continuously compare all available mAb for Covid-19 and can stop mAb arms based on internal statistical triggers or external factors, such as U.S. federal decisions limiting mAb availability or re-introduction of mAb into distribution networks. Had

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

federal decisions not prompted unblinding, the internal action would have been to generate updated randomization proportions and continue enrollment. The trial is currently evaluating casirivimab-imdevimab and sotrovimab.^{28,29} Systematic inequities have exacerbated racial health disparities throughout the Covid-19 pandemic, and a focused effort on equitable, expanded access to life-saving treatments is crucial for population health.³⁰ This trial was able to increase access using a multifaceted approach: 1) infrastructure with infusion locations in all geographic regions, 2) comprehensive, electronic screening of all patients within the system with a positive SARS-CoV-2 followed by direct-topatient outreach phone calls, 3) paper referral form for patients without access to an in-system provider, 4) community leader and existing outreach network collaboration for patient engagement, 5) phone line for patients and community members to call and speak with a healthcare professional, 6) providing infusions at home for patients without transportation. The finding of potential inferiority of bamlanivimab is similar to mechanistic studies that suggest a waning efficacy of bamlanivimab in the face of certain SARS-CoV-2 variants. It supports the FDA decision to revoke the bamlanivimab EUA.²⁶ A recent observational study reached a different conclusion and found similar effectiveness between bamlanivimab and casirivimabimdevimab.³¹ However, this study analyzed patients treated between November 2020 and February 2021, prior to widespread emergence of variants and U.S. federal decisions to halt bamlanivimab distribution.

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

SARS-CoV-2 variant epidemiology changes rapidly and this report addresses a period when the Alpha variant was dominant, and the Delta variant was not widespread. Notably, the U.S. federal government reinstated circulation of bamlanivimab-etesevimab on August 27, 2021 in areas where variant resistance to this mAb is < 5%, based on *in vitro* data of activity against the Delta variant, and lack of activity against the Beta, Gamma, Delta plus, and B.1.621 variants. ^{31,32} The similar effectiveness of bamlanivimab-etesevimab and casirivimab-imdevimab in the current trial supports this decision. Also aligning with these data is a recent observational study of 165 patients that found no difference in hospitalization or death between bamlanivimab-etesevimab and casirivimab-imdevimab in patients infected with Alpha, but worse outcomes with bamlanivimab-etesevimab in patients infected with Gamma.³³ The strengths of this report include capture of nearly all patients infused with mAb from 49 sites across a large geographic region, enhancing the generalizability of the results. In addition, an advantage of the Bayesian design is that any data, including data following unplanned cessation in enrollment into a trial arm, can be analyzed and quantified as posterior probabilities, which is potentially more useful and is more quantitative than a frequentist conclusion of failure to reject a null hypothesis possibly because of lack of power.³⁴ Third, the trial was embedded into usual care which enhanced patient and provider engagement. 12 The trial also has limitations. First, the results are presented before any prespecified internal trigger was reached. Nonetheless, to our knowledge, this trial represents the largest randomized comparative effectiveness data of mAb for Covid-19. Second, the absence of patient-level variant data limited ability to directly assess comparative effectiveness relative to variant strains. Alpha was also the dominant variant during

the majority of the trial. Using regional data as a surrogate for variant data in the Pennsylvania

population over time, we found no difference in treatment effect over time. Third, we primarily relied on UPMC EHR data to capture death and hospitalization, and patients may have accessed care outside our health system after mAb treatment. We conducted direct-to patient calls and national death registry queries to address this concern. Fourth, the EHR eligibility screen identified most, but not all EUA risk factors, and could not identify if a patient was symptomatic.

Conclusion

In non-hospitalized patients with mild to moderate Covid-19, bamlanivimab, compared to bamlanivimab-etesevimab and casirivimab-imdevimab, resulted in 91% and 94% probabilities of inferiority with regards to odds of improvement in hospital-free days within 28 days. There was an 86% probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab at an odds ratio bound of 0.25. However, the trial was unblinded early to these mAb due to federal distribution decisions, and no mAb met prespecified criteria for statistical inferiority or equivalence.

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

Acknowledgements: The authors thank the clinical staff of the UPMC monoclonal antibody infusion centers as well as the support and administrative staff behind this effort, including but not limited to: Michelle Adam, Jodi Ayers, Ashley Beyerl, Trudy Bloomquist, Mikaela Bortot, Jonya Brooks, Sherry Casali, Jeana Colella, Jennifer Dueweke, Jesse Duff, Janice Dunsavage, Jessica Fesz, Kathleen Flinn, Daniel Gessel, Amy Helmuth, Erik Hernandez, Larry Hruska, Allison Hydzik, Le Ann Kaltenbaugh, LuAnn King, Jim Krosse, Sheila Kruman, Amy Lukanski, Hilary Maskiewicz, Debra Masser, Katelyn Mayak, Rebecca Medva, Theresa Murillo, Melanie Pierce, Teressa Polcha, Kevin Pruznak, Debra Rogers, Rozalyn Russell, Sarah Sakaluk, Heather Schaeffer, Robert Shulik, Libby Shumaker, Susan Spencer, Betsy Tedesco, Ken Trimmer, Jennifer Zabala, and their entire teams. Donald M. Yealy, MD provided data and safety monitoring for the trial. Funding Statement: This work received no external funding. The U.S. federal government provided the monoclonal antibody treatments reported in this manuscript. **Conflict of Interest Disclosure:** None of the authors received any payments or influence from a third-party source for the work presented.

REFERENCES

- 1. Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human
- 350 coronaviruses. Trends Immunol. 2020 May;41(5):355-359. doi:10.1016/j.it.2020.03.007.
- 351 2. Bariola JR, McCreary EK, Wadas RJ, et al. Impact of bamlanivimab monoclonal antibody
- treatment on hospitalization and mortality among non-hospitalized adults with severe acute
- respiratory syndrome coronavirus 2 infection. Open Forum Infect Dis. 2021 May
- 354 17;8(7):ofab254. doi: 10.1093/ofid/ofab254.
- 355 3. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in
- outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):229-237. doi:
- 357 10.1056/NEJMoa2029849.
- 4. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate
- 359 Covid-19. N Engl J Med. 2021 Jul. doi:10.1056/nejmoa2102685.
- 360 5. Weinreich D, Sivapalasingam S, Norton T, et al. REGEN-COV antibody cocktail clinical
- outcomes study in COVID-19 outpatients. medRxiv. 2021 June 6. doi:
- 362 10.1101/2021.05.19.21257469.
- 363 6. U.S. Food and Drug Administration News Release. Coronavirus (COVID-19) update: FDA
- authorizes monoclonal antibody for treatment of COVID-19. 2020 November 9. Available at:
- https://bit.ly/2HesBBs. Accessed July 20, 2021.
- 366 7. U.S. Food and Drug Administration. Fact sheet for health care providers emergency use
- authorization (EUA) of bamlanivimab. Available at:
- 368 https://www.fda.gov/media/143603/download. Accessed July 20, 2021.

- 8. U.S. Food and Drug Administration. Fact sheet for health care providers emergency use
- authorization (EUA) of bamlanivimab and etesevimab. Available at:
- https://www.fda.gov/media/145802/download. Accessed July 20, 2021.
- 9. U.S. Food and Drug Administration. Fact sheet for health care providers emergency use
- authorization (EUA) of REGEN-COVTM. Available at:
- https://www.regeneron.com/downloads/treatment-covid19-eua-fact-sheet-for-hcp.pdf.
- 375 Accessed July 20, 2021.
- 376 10. Bernstein L, McGinley L. Monoclonal antibodies are free and effective against covid-19, but
- few people are getting them. The Washington Post. Published 20 Aug 2021. Accessed 28
- Aug 2021. Available from: https://www.washingtonpost.com/health/covid-monoclonal-
- 379 abbott/2021/08/19/a39a0b5e-0029-11ec-a664-4f6de3e17ff0_story.html
- 380 11. National Academies of Sciences, Engineering, and Medicine News Release. Strategies to
- allocate scarce COVID-19 monoclonal antibody treatments to eligible patients examined in
- new rapid response to government. 2021 January 29. Available at:
- https://www.nationalacademies.org/news/2021/01/strategies-to-allocate-scarce-Covid-19-
- monoclonal-antibody-treatments-to-eligible-patients-examined-in-new-rapid-response-to-
- 385 government. Accessed July 20, 2021.
- 386 12. Angus DC. Optimizing the Trade-off Between Learning and Doing in a Pandemic. JAMA
- 387 2020;323(19):1895-1896. DOI: 10.1001/jama.2020.4984.
- 388 13. Institute of Medicine (US) Roundtable on Evidence-Based Medicine. The Learning
- Healthcare System: Workshop Summary. Olsen L, Aisner D, McGinnis JM, editors.
- Washington (DC): National Academies Press (US); 2007. doi: 10.17226/11903.

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

14. Huang DT, McCreary EK, Bariola JR, et al. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization. Trials. 2021 May 25;22(1):363. doi: 10.1186/s13063-021-05316-3. 15. Angus D. Fusing randomized trials with big data: the key to self-learning health care systems? JAMA 2015;314:767-8. doi: 10.1001/jama.2015.7762. 16. Bariola JR, McCreary EK, Khadem T, et al. Establishing a distribution network for COVID-19 monoclonal antibody therapy across a large health system during a global pandemic. Open Forum Infect Dis. 2021 Mar 26;8(7):ofab151. doi: 10.1093/ofid/ofab151. 17. U.S. Department of Health & Human Services Public Health Emergency. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. 2021 April 16. Available at: https://www.fda.gov/news-events/pressannouncements/coronavirus-Covid-19-update-fda-revokes-emergency-use-authorizationmonoclonal-antibody-bamlanivimab. Accessed on July 20, 2021. 18. Reitz KM, Seymour CW, Vates J, et al. Strategies to Promote Resiliency (SPRY): a randomised embedded multifactorial adaptative platform (REMAP) clinical trial protocol to study interventions to improve recovery after surgery in high-risk patients. BMJ Open. 2020 Sep 29;10(9):e037690. doi: 10.1136/bmjopen-2020-037690. 19. Centers for Medicare and Medicaid Services. Meaningful use data; public use files – CMS. Available at: www.cms.gov. Accessed September 3, 2021.

- 412 20. Christainsen SL, Cintron MY, Desai A, et al. American Medical Association Manual of Style,
- 413 *I1*th edition, a guide for authors and editors. Oxford University Press 2020. Available at:
- www.amamanualofstyle.com. Accessed September 3, 2021.
- 21. Kind AJH, Buckingham W. Making neighborhood disadvantage metrics accessible: the
- 416 neighborhood atlas. N Engl J Med. 2018. 378: 2456-2458. doi: 10.1056/NEJMp1802313.
- 22. University of Wisconsin School of Medicine Public Health. 2015 Area Deprivation Index
- v2.0. Downloaded from https://www.neighborhoodatlas.medicine.wisc.edu/ August 1, 2021.
- 419 23. Global Initiative on Sharing Avian Influenza Data. Tracking of variants. Available at
- https://www.gisaid.org/. Accessed on July 20, 2021.
- 421 24. Social Security Administration. Social Security Master File of Social Security Number
- 422 Holders and Applications: Death Information. Available at:
- https://www.ssa.gov/dataexchange/request_dmf.html. Accessed August 1, 2021.
- 424 25. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an
- extension of the CONSORT statement. BMJ. 2008 Nov 11;337:a2390. doi:
- 426 10.1136/bmj.a2390.
- 427 26. U.S. Department of Health & Human Services Public Health Emergency. Coronavirus
- 428 (COVID-19) Update: FDA revokes emergency use authorization for monoclonal antibody
- bamlanivimab. 2021 April 16. Available at: https://www.fda.gov/news-events/press-
- announcements/coronavirus-Covid-19-update-fda-revokes-emergency-use-authorization-
- 431 monoclonal-antibody-bamlanivimab. Accessed on July 20, 2021.
- 432 27. U.S. Department of Health & Human Services Public Health Emergency. Pause in the
- distribution of bamlanivimab/etesevimab. 2021 June 25. Available at:
- 434 https://www.phe.gov/emergency/events/COVID19/investigation-MCM/BamlanivimAb-

- etesevimAb/Pages/bamlanivimAb-etesevimAb-distribution-pause.aspx. Accessed on July 20,
- 436 2021.
- 437 28. U.S. Department of Health & Human Services. Federal response to COVID-19: monoclonal
- antibody update. 2021 July 30. Available at:
- https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Documents/USG-
- 440 COVID19-Tx-Playbook.pdf. Accessed August 1, 2021.
- 29. Food and Drug Administration. Fact sheet for healthcare providers: emergency use
- authorization (EUA) of sotrovimab. 2021. Available
- at: https://www.fda.gov/media/149534/download. Accessed on July 20, 2021.
- 30. Ganesh R, Philpot LM, Bierle DM, et al. Real-world clinical outcomes of bamlanivimab and
- casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease
- 446 2019. J Infect Dis. 2021 Jul 19:jiab377. doi: 10.1093/infdis/jiab377.
- 31. Falcone M, Tiseo G, Valoriani B, et al. Efficacy of Bamlanivimab/Etesevimab and
- 448 Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of
- Variants of Concern [published online ahead of print, 2021 Aug 25]. *Infect Dis Ther.* 2021;1-
- 450 10. doi:10.1007/s40121-021-00525-4
- 451 32. Connor BA, Couto-Rodriguez M, Barrows JE, et al. Monoclonal antibody therapy in a
- vaccine breakthrough SARS-CoV-2 hospitalized Delta (B.1.617.2) variant case. Int J Infect
- 453 Dis. 2021 Jul 13;110:232-234. doi: 10.1016/j.ijid.2021.07.029.
- 454 33. Planas D, Veyer D, Baidaliuk A. Reduced sensitivity of infectious SARS-CoV-2 variant
- B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals.
- 456 bioRxiv. 2021 May 27. doi: 10.1101/2021.05.26.445838.

457 34. Quintana M, Viele K, Lewis RJ. Bayesian Analysis: Using Prior Information to Interpret the

458

459

Results of Clinical Trials. JAMA. 2017;318(16):1605–1606. doi:10.1001/jama.2017.15574

TABLES

Table 1. Demographic and Clinical Characteristics of the Patients at Baseline and

Comparison by Monoclonal Antibody Group.

Comparison by Monoclonal Anti	body Group.			
		Bamlanivimab	Casirivimab	Entire
Characteristic	Bamlanivimab	– etesevimab	-imdevimab	Cohort
	(n =128)	(n = 885)	(n = 922)	(n = 1,935)
Age, mean (SD)	57 (17)	56 (16)	55 (16)	56 (16)
Female sex, n (%)	69 (54%)	470 (53%)	502 (54%)	1,041 (54%)
Race, n (%) ‡				
White	104 (81%)	693 (78%)	701 (76%)	1,498 (77%)
Black	15 (12%)	148 (17%)	173 (19%)	336 (17%)
Other	1 (0.8%)	23 (2.6%)	27 (2.9%)	51 (2.6%)
Unknown	8 (6.3%)	21 (2.4%)	21 (2.3%)	50 (2.6%)
Vaccine status				
Fully vaccinated	2 (1.6%)	43 (4.9%)	19 (2.1%)	64 (3.3%)
Partially vaccinated	26 (20%)	39 (4.4%)	55 (6.0%)	120 (6.2%)
Unvaccinated	0 (0%)	27 (3.1%)	30 (3.3%)	57 (2.9%)
Unknown	100 (78%)	776 (88%)	818 (89%)	1,694 (88%)
Body mass index, mean (SD)	35.6 (9.1)	34.5 (8.4)	35.1 (8.4)	34.8 (8.4)
Days from randomization to infusion, mean (SD)	0.6(0.9)	0.4(0.7)	0.4(0.8)	0.4(0.8)
Days from symptoms to randomization, mean (SD)	5.0 (2.0	5.4 (2.0)	4.9 (2.0)	5.0 (2.1)
Days from symptoms to infusion, mean (SD)	6.3 (1.8)	6.0 (1.9)	6.2 (2.0)	6.1 (1.9)
Location				
Infusion center	103 (81%)	463 (52%)	462 (50%)	1,028 (53%)
Emergency department	25 (20%)	422 (48%)	460 (50%)	907 (47%)
Qualifying EUA criteria	, ,	, ,	· · ·	, ,
March 10, 2021 – May 23, 2021	128 (100%)	753 (85%)	783 (85%)	1,664 (86%)
Age \geq 65 years	39 (31%)	223 (30%)	236 (30%)	498 (30%)
Body mass index ≥ 35	33 (47%)	238 (47%)	257 (49%)	528 (48%)
Chronic kidney disease	4 (4.0%)	43 (7.7%)	51 (8.8%)	98 (7.9%)
Diabetes	24 (24%)	154 (28%)	154 (27%)	332 (27%)
Immunosuppressive disease or treatment §	26 (26%)	158 (28%)	155 (27%)	339 (27%)
Sickle cell disease	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Age \geq 55 years and	` '	` '	, ,	` ,
Cardiovascular disease	29 (26%)	112 (17%)	117 (17%)	258 (18%)
Hypertension	43 (39%)	224 (35%)	223 (33%)	490 (34%)
Respiratory condition	29 (26%)	124 (19%)	119 (18%)	272 (19%)
Age 12-17 years with qualifying criterion	1 (0.8%)	13 (1.7%)	6 (0.8%)	20 (1.2%)
May 24, $2021 - \text{June } 25, 2021 \P$	0 (0%)	132 (15%)	139 (15%)	271 (14%)
Age \geq 65 years	-	30 (23%)	37 (27%)	67 (25%)
Body mass index >25	_	88 (89%)	90 (90%)	178 (89%)
Chronic kidney disease	_	7 (6.6%)	7 (6.5%)	14 (6.5%)
Diabetes	_	29 (27%)	25 (23%)	54 (25%)
Down syndrome	_	0 (0%)	0 (0%)	0 (0%)
Current or former smoker	_	25 (31%)	32 (37%)	57 (34%)
Current or history of substance abuse	_	0 (0%)	2 (2.3%)	2 (1.2%)
Immunosuppressive disease or treatment	_	29 (27%)	27 (25%)	56 (26%)
Sickle cell disease	_	0 (0%)	0 (0%)	0 (0%)
Cardiovascular disease	_	24 (23%)	14 (13%)	38 (18%)
Hypertension	_	61 (58%)	52 (48%)	113 (53%)
Respiratory condition	_	42 (40%)	40 (37%)	82 (38%)
Liophator, condition		12 (10/0)	10 (31/0)	02 (3070)

		Age 12-17 years with qualifying criterion - 1 (0.8%) 2 (1.4%) 3 (1.1%)				
466	*	SD, standard deviation; EUA, emergency use authorization.				
467	†	Percentages shown correspond to those patients within each time period. Race was				
468		reported by the patients.				
469	‡	Race was reported by the patients.				
470	§	Immunosuppressive disease or treatment was defined as a history of HIV, cancer,				
471		transplant (solid organ, stem cell, bone marrow), chemotherapy treatment, lupus,				
472		rheumatoid arthritis, or liver disease.				
473	\P	EUA criteria were expanded May 14, 2021, and operationalized at UPMC May 24, 2021.				
474						
475						
476						
477						
478						

Table 2. Primary Outcomes and Analysis.

479

480

Table 2. I finally Outcomes and Analys		Bamlanivimab	Casirivimab
Outcome/analysis	Bamlanivimab	-etesevimab	-imdevimab
·	(n = 128)	(n = 885)	(n = 922)
Primary outcome, hospital-free days, median			
(IQR)	28 (28-28)	28 (28-28)	28 (28-28)
Patients with 28 hospital-free days, n (%)	112 (87.5%)	755 (85.3%)	790 (85.7%)
Subcomponents of hospital-free days			
Deaths, n (%)	1 (0.8%)	7 (0.8%)	6 (0.7%)
Hospital length of stay among hospitalized			
patients, median days (IQR)	4 (2-10)	4 (3-7)	3 (2-6)
Hospitalized, n (%)	16 (12.5%)	130 (14.7%)	132 (14.3%)
After mAb infusion in emergency			
department	8 of 25 (32.0%)	100 of 422 (23.7%)	100 of 460 (21.7%)
After mAb infusion in infusion center	8 of 103 (7.8%)	30 of 463 (6.5%)	32 of 462 (6.9%)
Primary analysis of the primary outcome			
Adjusted odds ratio			
Mean (SD)	0.62 (0.22)	0.95 (0.13)	1 [Reference]
Median (95% credible interval)	0.58 (0.30 to 1.16)	0.94 (0.72 to 1.24)	1 [Reference]
Probability of inferiority to bamlanivimab-			
etesevimab, %	91%	-	34%
Probability of inferiority to casirivimab-			
imdevimab, %	94%	66%	-
Probability of equivalence between			
bamlanivimab-etesevimab and casirivimab-			
imdevimab within an odds ratio bound of, %			
0.25	=	86	5%
0.20	-	77	7%
0.15	-	64	1%
0.10	-	47	7%
0.05		25	5%

* IQR, interquartile range; mAb, monoclonal antibodies; SD, standard deviation.

482

483

484

485

486

487

488

489

490

491

492

493

494 495

496 497

498

499

500

501

502

FIGURE LEGENDS Figure 1. Epidemiology of Monoclonal Antibody Infusions. Panel A shows the number of mAb-infused patients among the EHR screen eligible. Panel B shows the proportion of mAb-infused patients among EHR screen eligible by White or Black race. Hispanic ethnicity, Other, and Unknown race are not shown due to small sample sizes. Panel C shows the number of mAb infusions per 1,000 cases prior to March 10, 2021. Panel D shows the number of mAb infusions per 1,000 cases after March 10, 2021. Zip codes with <10 Covid-19 cases or those outside of Pennsylvania are not shown. Interpretive example: Prior to the trial (panel A), mAb infusion was low. In panel B, the proportion of White and Black race infused among EHR-screen eligible patients increased. In the UPMC catchment in Pennsylvania, mAb infusions also increased in amount (darker, panel C, D) and in geographic distribution (more zip code areas colored) during OPTIMISE-C19. Figure 2. CONSORT Diagram. Due to pharmacy logistics, 5 patients who received bamlanivimab-etesevimab had been randomly assigned to casirivimab-imdevimab, and 7 patients who received casirivimabimdevimab had been randomly assigned to bamlanivimab-etesevimab. All infused patients who received bamlanivimab monotherapy had been randomly assigned to bamlanivimab monotherapy. The FDA mAb policies changed over time, resulting in varying mAb availability and EUA eligibility criteria over time (**Supplement**).

Figure 3. Hospital-Free Days to Day 28. Primary outcome is displayed as horizontally stacked proportions by monoclonal antibody type. Red represents worse values and blue represents better values. The median adjusted odds ratio from the primary analysis, using a Bayesian cumulative logistic model, were 0.58 (95% credible interval, 0.30 to 1.16) and 0.94 (95% credible interval, 0.72 to 1.24) for the bamlanivimab and bamlanivimab-etesevimab groups compared with the casirivimab-imdevimab group. These odds ratios yielded 91% and 94% probabilities of inferiority of bamlanivimab versus bamlanivimabetesevimab and casirivimab-imdevimab respectively, and an 86% probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab at an odds ratio bound of 0.25.




Figure 1. Epidemiology of Monoclonal Antibody Infusions.




Figure 2. CONSORT Diagram.




Figure 3. Hospital-Free Days to Day 28.

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: A learning health system randomized trial of monoclonal antibodies for Covid-19

Table of Contents Trial Design **Analytical Methods** Table S1. Department of Health and Human Services – Food and Drug Administration's Emergency Use Authorizations and UPMC Monoclonal Antibody Policy Changes Over Time Table S2. Adverse Events in Patients Receiving Monoclonal Antibody Treatment Figure S1. Treatment Heterogeneity Across Variant Date Prevalence Epochs Figure S2. SARS-CoV-2 Variants of Concern Proportion in Pennsylvania During the Study Figure S3. Monoclonal Antibody Referral Order in EPIC Figure S4. Monoclonal Antibody Referral Order in Cerner

Section 1 – Supplementary Methods

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

Trial Design: Several problems may be encountered when generating robust clinical evidence, including barriers to conducting clinical trials, the generalisability of data from populations that are too broad or too narrow, the issue of equipoise especially when comparing different types of existing care, and the delay in translating results into clinical practice. A Randomized Embedded Multifactorial Adaptive Platform (REMAP) provides a strategy to address many of these problems by gaining economies of scale from a common platform, which allows for broad enrollment but retaining the ability to examine for heterogeneity of treatment effects between defined subgroups. A REMAP focuses predominantly on the evaluation of treatment options for the disease of interest that are variations within the spectrum of standard care (although testing of novel or experimental therapies is not precluded) and does so by embedding the trial within routine healthcare delivery. In this regard, the REMAP seeks to replace random variation in treatment with randomized variation in treatment allowing causal inference to be generated about the comparative effectiveness of different existing treatment options. The use of response adaptive randomization (RAR), which allows the allocation ratios to change over time based on accruing outcomes data, maximises the chance of good outcomes for trial participants. The embedding of such a platform within the day-to-day activities facilitates the translation of outcomes to clinical practice as a "self-learning" system. As such, it also functions as an embedded and automated continuous quality-improvement program. A final advantage of a REMAP for optimizing monoclonal antibody treatment outcomes is the ability to rapidly adapt to generate evidence if as new interventions emerge, avoiding the inevitable delays associated with conventional trials.

A REMAP applies novel and innovative trial adaptive design and statistical methods to evaluate a range of treatment options as efficiently as possible. The broad objective of a REMAP is, over time, to determine and continuously update the optimal set of treatments for the disease of interest. The set of treatments that may be tested within a REMAP comprise the set of all treatments that are used currently or may be developed in the future and used or considered for use in patients. The design maximizes the efficiency with which available sample size is applied to evaluate treatment options as rapidly as possible. A REMAP has the capacity to identify differential treatment effects in defined sub-groups (termed strata), address multiple questions simultaneously, and can evaluate interactions among selected treatment options. Throughout the platform, patients who are enrolled in the trial are treated as effectively as possible. A conventional RCT (i.e., a non-platform trial) makes a wide range of assumptions at the time of design. These assumptions include the plausible size of the treatment effect, the incidence of the primary outcome, the planned sample size, the (typically, small number of) treatments to be tested, and that treatment effects are not influenced by concomitant treatment options. These assumptions are held constant until the trial completes recruitment and data are analyzed. Participants who are enrolled in a conventional RCT are not able to benefit from knowledge accrued by the trial because no results are made available until the trial completes. A REMAP uses five approaches to minimise the impact of assumptions on trial efficiency and maximises the benefit of participation for individuals who are enrolled in the trial. These design features are:

- frequent adaptive analyses using Bayesian statistical methods
- response adaptive randomization

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

• evaluation of differential treatment effects in pre-specified sub-groups (strata) evaluation of specified intervention-intervention interactions testing of multiple interventions in parallel and, subsequently, in series This creates a 'perpetual trial' with no pre-defined sample size, the objective of which is to define and continuously update best treatment over the lifetime of the REMAP. The design aspects, including the risk of type I and type II errors, are optimized prior to the commencement of the trial by the conduct of extensive pre-trial Monte Carlo simulations, modification of the trial design, and re-simulation in an iterative manner. The methods related to the application of the design features and the statistical analysis of this trial are outlined in the methods section of the protocol. A separate **Protocol Appendix** contains detailed versions of the protocol with relevant protocol amendments and the statistical analysis plan. Analytical Methods: Within the REMAP, two or more interventions are evaluated, and sequential Bayesian statistical analyses are used over time to incorporate new trial outcome information to determine if an intervention is superior, if one or more interventions are inferior, or if two or more interventions are equivalent, in comparison to all other interventions with respect to the primary endpoint. Every participant will be assigned an intervention. Inference in this REMAP is determined by analyses using pre-specified statistical models that incorporate time periods, age, and disease severity to adjust for heterogeneity of enrolled participants that might influence risk of death. These models incorporate variables that represent each intervention assigned to participants. The efficacy of each intervention is modeled as possibly varying in the different stratum in the REMAP.

Whenever a model hits a predefined threshold for any of superiority, inferiority, or equivalence for an intervention with respect to the primary endpoint, this is termed a statistical trigger. At any given adaptive analysis, a statistical trigger may be reached for all participants or for one or more strata, further described in the statistical analysis plan (**Protocol Appendix, page 26**).

Section 2 – Supplementary Tables

Table S1. Department of Health and Human Services – Food and Drug Administration mAb Emergency Use Authorizations and UPMC Policy Changes Over Time.

Date	Change	Explanation
9-Nov-2021	HHS/FDA provides mAb EUAs and treatment for COVID-19 eligibility criteria	Eligibility Criteria - High risk is defined as patients who meet at least one of the following criteria: • Have a body mass index (BMI) ≥35 • Have chronic kidney disease • Have diabetes • Have immunosuppressive disease • Are currently receiving immunosuppressive treatment • Are ≥65 years of age • Are ≥55 years of age AND have o cardiovascular disease, OR o hypertension, OR o chronic obstructive pulmonary disease/other chronic respiratory disease. • Are 12 − 17 years of age AND have o BMI ≥85th percentile for their age and gender based on CDC growth charts, OR o sickle cell disease, OR o congenital or acquired heart disease, OR o neurodevelopmental disorders, for example, cerebral palsy, OR o a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR o asthma, reactive airway or other chronic respiratory disease that requires daily medication for control. EUAs for • bamlanivimab • bamlanivimab • bamlanivimab-imdevimab
10-Mar-2021	UPMC – Opened study enrollment	Go-live date for trial with bamlanivimab and casirivimab-imdevimab only and following COVID-19 Treatment Guidelines.
16-Mar-2021	UPMC - Incorporation of bamlanivimab- etesevimab into random allocation	Start incorporating bamlanivimab- etesevimab into most sites. There was a 1-week delay to use etesevimab at six sites due to low initial supply.

23-Mar-2021	UPMC - mAb treatment expanded to Emergency Departments	Based on published data from our health system demonstrating significant decrease in hospitalizations and deaths with bamlanivimab (Bariola OFID 2021), the decision was made to invest resources in Emergency Department expansion to increase access to mAb treatment.
25-Mar-2021	HHS/FDA EUA for distribution of bamlanivimab alone was halted	A memorandum on the Fact Sheet for bamlanivimab alone – Update was issued on 3/17/21. Pseudovirus neutralization data for SARS-CoV-2 variant substitutions with bamlanivimab alone was unsuccessful.
31-Mar-2021	UPMC – stopped bamlanivimab alone	Emerging data about lack of efficacy with SARS-COV-2 variants resulted in System COVID-19 Pharmacy & Therapeutics Committee's decision to remove bamlanivimab alone from formulary. All sites put on view to use bamlanivimab only with etesevimab.
16-Apr-2021	HHS/FDA EUA for bamlanivimab was revoked	EUA revoked due to lack of efficacy with SARS-COV-2 variants.
25-Apr-2021	UPMC - Protocol Amendment 1 to remove use of bamlanivimab alone	Updated trial protocol to reflect clinical practice of not using bamlanivimab alone.
26-Apr-2021	UPMC – expanded study enrollment to observation status patients	Established process for treating observation status patients at UPMC hospitals.
6-May-2021	UPMC - Interim Analysis	Data supported it was safe to proceed.
14-May-21	HHS/FDA EUA expands eligibility criteria	Eligibility Criteria - The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40 kg) at higher risk for progression to severe COVID-19: • Older age (for example age ≥65 years of age) • Obesity or being overweight (for example, adults with BMI >25 kg/m2 or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts • Pregnancy • Chronic kidney disease • Diabetes • Immunosuppressive disease or immunosuppressive treatment • Cardiovascular disease (including congenital heart disease) or hypertension • Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung

26-May-21	HHS/FDA provides an EUA for sotrovimab	disease, cystic fibrosis, and pulmonary hypertension) • Sickle cell disease • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies) • Having a medical-related technological dependence (e.g., tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19]) Sotrovimab is a new mAb treatment.
3-June-2021	HHS/FDA EUA revised to decrease dose for casirivimab-imdevimab	Casirivimab 600mg and imdevimab 600 mg
15-June-2021	UPMC - decreased dose for casirivimab-imdevimab	Casirivimab-imdevimab dose decreased from 2400mg to 1200mg.
25-June-2021	HHS/FDA EUA for distribution of bamlanivimab-etesevimab was paused	FDA recommends not to use bamlanivimabetesevimab together.
25-June-2021	UPMC - stopped bamlanivimab-etesevimab	UPMC pulls from shelves.
25-June-2021	UPMC - Protocol Amendment 2: remove bamlanivimab-etesevimab add sotrovimab update EUA expanded eligibility criteria	Updated trial protocol to reflect clinical practice of not using bamlanivimabetesevimab, add use of sotrovimab, and expanded eligibility criteria.

^{*} mAb, monoclonal antibodies; HHS/FDA, Department of Health and Human

Services/Food and Drug Administration; EUA, emergency use authorization.

Table S2. Adverse Events in Patients Receiving Monoclonal Antibody Treatment.

661

Patient	mAb	Mild	Severe	Monocional Antibody Treatment.
ID	Received	Reaction	Reaction	Reaction Description
	Bamlanivimab +			Hypoglycemic, hypotension: infusion stopped treated with
1	Etesevimab	Y		diphenhydramine and fluid, patient discharged stable to
				home.
2	Bamlanivimab +	3.7		Patient developed tightness in head/sinus area, and
2	Etesevimab	Y		tightness in chest. Infusion not finished. Discharged home.
3	Bamlanivimab +	Y		Patient reported chest tightness, became lightheaded and
3	Etesevimab	1		dizzy. Infusion not finished. Discharged home.
4	Bamlanivimab +	Y		Patient developed hypotension; responded to 500mL LR,
	Etesevimab	1		discharged home normotensive.
5	Bamlanivimab +	Y		Headache, responded to acetaminophen.
	Etesevimab	1		
6	Bamlanivimab +	Y		Flushed, chest pain. Stopped infusion.
	Etesevimab			T 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
7	Bamlanivimab +	Y		Low back pain, radiating. Decreased infusion rate in half.
	Etesevimab			Patient stated pain alleviated and denied any complaints
8	Bamlanivimab + Etesevimab	Y		Patient reported nausea, hot flash, severe lower back pain 1 minute into infusion.
	Bamlanivimab +			Patient stated flushed/throat "closing". Stopped infusion.
9	Etesevimab		Y	Sent to ED for evaluation.
	Bamlanivimab +			Flushing and shortness of breath.
10	Etesevimab	Y		ridshing and shortness of oreadi.
	Bamlanivimab +	**		Mild itchiness and redness at infusion site.
11	Etesevimab	Y		
12	Bamlanivimab +	N/		Became itchy, developed hives, received
12	Etesevimab	Y		diphenhydramine.
13	Casirivimab +	Y		Headache.
13	Imdevimab	1		
	Casirivimab +			Sudden onset nausea, vomiting, and weakness after 1 hour
14	Imdevimab		Y	observation period; checked into ED and admitted post
				infusion
15	Casirivimab +	Y		Patient developed dizziness and chills which resolved
	Imdevimab			prior to discharge.
16	Casirivimab +	Y		Right before discharge patient mentioned dizziness and
	Imdevimab			lower blood pressure. Discharged to home.
17	Casirivimab + Imdevimab		Y	Hypertension and headache post-infusion, transferred to ED.
	Casirivimab +			Patient became hot, red face, reported chest pain 9/10.
18	Imdevimab		Y	Oxygen saturation went from 95 to 85 to 73. Sent to ED.
	Casirivimab +			Chills, flushing, chest tightness, headache. Infusion
19	Imdevimab	Y		stopped.
20	Casirivimab +		*7	Chest pain, shortness of breath, and back pain 2 minutes
	Imdevimab		Y	into infusion. Paramedics called.
21	Casirivimab +	V		Shortness of breath, chest tightness 3 minutes into
21	Imdevimab	Y		infusion. Medication stopped and symptoms resolved.

Section 4 – Supplementary Figures




Figure S1. Treatment Heterogeneity Across Variant Date Prevalence Epochs.




Figure S2. SARS-CoV-2 Variants of Concern Proportion in Pennsylvania During the Study

CONSULT / REFERRAL TO	D COVID MONOCLONAL ANTIBODY MEDICATION	✓ Accept			
Eligibility Criteria (select all that apply):	☐ Age >/= 65 years ☐ BMI >/= 25 (adults) ☐ BMI >/= 85 percentile (age 12-17) ☐ Pregnancy				
	☐ Chronic kidney disease ☐ Cardiovascular disease ☐ Hypertension ☐ Diabetes				
	□ Down syndrome □ Dementia □ Liver disease □ Current or former smoker				
	☐ Current or history of substance abuse				
	☐ Immunosuppressive disease or immunosuppressive treatment				
	☐ History of stroke or cerebrovascular disease ☐ Chronic lung disease ☐ Sickle cell disease				
	☐ Neurodevelopmental disorders or other conditions that confer medical complexity				
	☐ Having a medical-related technological dependence (e.g., tracheostomy, gastrostomy)				
	□ None - PATIENT NOT ELIGIBLE				
Date of Symptom Onset	(Fever, Cough, Sore throat, Malaise, Headache, Muscle pain, GI symptoms, or SOB w/ exertion):				
	ä				
Date of positive COVID-	19 Test (see comments for last test recorded in Epic):				
	ti i				
Is the patient pregnant or breastfeeding?	YES NO UNKNOWN				
Does patient have a new	or increasing oxygen requriement?				
	Yes No				
Vaccine status:	Fully vaccinated Partly vaccinated Unvaccinated Unknown				
Preferred Infusion	Pittsburgh (South Side) Altoona (age 12 & up) Chautauqua Cole East Hamot Jameson				
Center:	Passavant - Cranberry (Saturday only) Passavant - McCandless (age 12 & up) Pinnacle - Carlisle				
	Pinnacle - Hanover Pinnacle - Harrisburg (age 12 & up) Pinnacle - Lititz Pinnacle - York				
	Somerset (age 12 & up) Susquehanna - Wellsboro Susquehanna - Williamsport (age 12 & up)				
		WPIC (Behavioral Health only)			
	WPIC (Behavioral Health only)				
Second Choice Infusion	WPIC (Behavioral Health only) Pittsburgh (South Side) Altoona (age 12 & up) Chautauqua Cole East Hamot Jameson				
Second Choice Infusion Center:					
	Pittsburgh (South Side) Altoona (age 12 & up) Chautauqua Cole East Hamot Jameson				

 ${\bf Figure~S3.~Monoclonal~Antibody~Referral~Order~in~EPIC.}$




Figure S4. Monoclonal Antibody Referral Order in Cerner.

Protocol Appendix

This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol for: A learning health system randomized trial of monoclonal antibodies for Covid-19

Protocol and Statistical Analysis Plan This appendix contains the following items: 1. The original protocol document, final protocol document, and summary of changes. 2. The statistical analysis plan. Relevant protocol documents included in this supplement are: **OPTIMISE-C19 Protocol** Summary of Changes25 -Amendment 1, Protocol Version 1.1, April 25, 2021 -Amendment 2, Protocol Version 1.2, June 30, 2021 Statistical Analysis Plan Overall Analysis Plan26 References31

ORIGINAL VERSION 1.0, February 24, 2021

A pragmatic evaluation of monoclonal antibody treatments in participants with COVID-19 illness (ClinicalTrials.gov, NCT04790786)

Summary

713

714

715716

717 718

Background

- FDA Emergency Use Authorizations (EUA) exist for multiple monoclonal antibodies (mAB) to treat COVID-19; the EUAs stipulate eligibility criteria, patient-physician communication, and clinical monitoring.¹
- UPMC provides mABs as routine care; physicians order a mAB infusion and pharmacies assign whichever mAB is available under a therapeutic interchange approach. If scarcity exists, a lottery system is used.
- Physicians review with patients the EUA Fact Sheet for each mAB and explain they could be assigned any of the EUA-governed mABs.²⁻

Approach

- Structure the therapeutic interchange policy and lottery system using a UPMC pharmacy embedded assignment system that allows a comparative effectiveness evaluation of the multiple mABs.⁵
- Collect data from clinically performed UPMC processes and EUA requirements for routine care.

Treatments Inclusion

Criteria

• Monoclonal antibodies (mAB) for COVID-19

These criteria are as per the FDA EUAs for COVID-19 mABs as of February 24, 2021.¹

- Adult and pediatric patients (12 years of age and older weighing at least 40 kg) with a positive SARS-CoV-2 antigen or PCR test and within 10 days of symptom onset, and high risk of disease progression
- High risk is defined as patients who meet at least one of the following criteria:
 - o Body Mass Index (BMI) ≥35
 - Have Chronic Kidney Disease
 - Have diabetes
 - Have immunosuppressive disease
 - Are currently receiving immunosuppressive treatment
 - Are \geq 65 years of age
 - o Are \geq 55 years of age AND have:
 - o cardiovascular disease, OR
 - o hypertension, OR
 - o chronic obstructive pulmonary disease/other chronic respiratory disease
 - o Are 12-17 years of age AND have:
 - o BMI ≥ 85th percentile for their age and gender based on CDC growth charts, OR

- o sickle cell disease, OR
- o congenital or acquired heart disease, OR
- o neurodevelopmental disorders (e.g., cerebral palsy),

OR

- o a medical-related technological dependence, for example, tracheostomy or gastrostomy), OR
- o asthma, reactive airway, or other respiratory disease that requires daily medication for control.

Exclusion Criteria

These criteria are as per the FDA EUAs for COVID-19 mABs as of February 24, 2021.¹

- Are hospitalized for the treatment of COVID-19
- Require oxygen therapy for the treatment of COVID-19
- Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity
- Have a known hypersensitivity to any antibody ingredient

Primary evaluation metric

719 720 721 Total hospital free days at 28 days

722 **Table of Contents** 723 **ABBREVIATIONS** 52 1. 724 BACKGROUND and RATIONALE 52 2.1. 725 2.2. 726 **OBJECTIVES AND METRICS** 727 54 728 3.1. 729 730 4. **DESIGN** 55 731 4.1. INCLUSION CRITERIA.......55 732 4.1.1. 4.1.2. 733 EXCLUSION CRITERIA56 734 5. **EVALUATED TREATMENTS** 5.1. 735 5.2. 736 737 5.3. CONCOMITANT THERAPY......57 738 **CONDUCT** 739 6. 740 6.1. 741 6.2. ANTIBODY ADMINISTRATION58 6.3. 742 743 6.4. mAB assignment59 STATISTICAL CONSIDERATIONS 744 745 7.1. STRATA59 746 7.2. NUMBER of PARTICIPANTS60 747 7.3. 748 8. ETHICAL CONSIDERATIONS 749 8.1. 750 8.2. 8.3. 751 752 8.3.1. SAFETY and RISK MITIGATION......61 753 8.3.2. 754 **EXHIBITS** 61 755 756 757 758 759 760

1. ABBREVIATIONS

761762763

764

765

766

767

768

769

770 771

772

773

774

775

AE Adverse Events
B bamlanivimab

B + E bamlanivimab and etesevimab

BMI Body Mass Index

C + I casirivimab + imdevimab

CDC Centers for Disease Control and Prevention COPD Chronic Obstructive Pulmonary Disease

COVID-19 Coronavirus disease 2019 CVD Cardiovascular Disease

EUA Emergency Use Authorization FDA Food and Drug Administration HHS Health and Human Services

HFD Hospital Free Days

HTN Hypertension kDa Kilodaltons

IgG1 Immunoglobulin G1

KG Kilograms

mAB Monoclonal Antibodies
PCR Polymerase Chain Reaction
SAEs Serious Adverse Events

SARS-CoV- Severe Acute Respiratory Syndrome

2 Coronavirus 2

UATRC UPMC Antibody Treatment and Evaluation

Center

2. BACKGROUND and RATIONALE

3. BACKGROUND

While COVID-19 vaccination will reduce COVID-19-related morbidity and mortality, the learned immune response may vary between individuals. This means interventions such as monoclonal antibodies (mAB) will still be needed to prevent progression of COVID-19 illness. Monoclonal antibodies seek to mimic or enhance the natural immune system response against a pathogen and are often used in the care of patients with cancer or infection.

776 For viral infections, mABs are created by exposing a white blood cell to a particular viral protein, 777 which is then cloned to mass produce antibodies to target that virus. For SARS-CoV-2, the virus 778 that causes COVID-19, IgG1 mABs target the spike protein of SARS-CoV-2 and block viral 779 attachment and entry into cells. 780 The SARS-CoV-2 mABs bamlanivimab and etesevimab, and the REGN-COV2 combination 781 (casirivimab + imdevimab) reduce nasopharyngeal viral burden plus clinical outcomes including 782 future emergency department visits and hospitalizations (Weinreich 33332778 NEJM, Gottlieb 783 33475701). Each received FDA Emergency Use Authorization (EUA) for use in selected 784 populations (Exhibit). Additional trials of pre-exposure prophylaxis (NCT04497987) and other 785 applications are underway, and additional mABs are in development. 786 The trials demonstrated the greatest impact of the REGN-COV2 dual therapy among patients who 787 lacked neutralizing antibodies against SARS-CoV-2 at baseline and in those with high 788 nasopharyngeal viral loads. Additionally, few patients in the bamlanivimab/etesevimab trial 789 developed treatment-emergent SARS-CoV-2 resistance. This latter phenomenon may further 790 enhance the need for therapies given the recent emergence of SARS-CoV-2 variants that may escape vaccination. However, the relative effectiveness of each mAB compared to the other is 791 792 unknown, as is their effectiveness for emerging virus variants. 793 This Appendix to the UPMC Pilot Core (PittPro 20040210) describes the approach of the UPMC 794 Antibody Treatment and Evaluation Center. We will conduct a pragmatic evaluation of 795 monoclonal antibody treatments in participants with COVID-19 illness, starting with the patient 796 population approved under the current FDA mAB EAUs. 797 798 4. **RATIONALE** 799 800 As of February 2021, there are over 60,000 new cases of COVID-19 diagnosed daily in the US 19 related hospital admissions Microsoft Power BI (powerbigov.us). Although case volumes are

- 801 https://covid.cdc.gov/covid-data-tracker/#trends dailytrendscases, with over 7000 daily COVID-
- 802
- 803 currently declining, COVID-19 remains a significant public health threat.
- 804 Despite the EUAs, the clinical use of mABs is low due in part to lack of patient access,
- 805 complexities in drug allocation, and lack of knowledge among providers are contributing factors.
- 806 Further, the comparative effectiveness of different mABs is unknown and not yet directly studied.
- 807 The National Academies of Sciences, Engineering, and Medicine recently called for expanded

809

810

811

812

813

814 815

816

817818

819

820

821

822 823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

access and clinical use of mABs, noting it is "critical to collect data and evaluate whether they are working as predicted". This evaluation seeks to expand access to mABs at UPMC and determine their relative effects versus each other, starting with those governed by EUAs. 5. **OBJECTIVES AND METRICS OBJECTIVES** 6. The primary objective is to evaluate the clinical and biological effect of multiple monoclonal antibodies (mABs) in patients with COVID-19. The primary hypothesis is clinical and biological effect will vary between mABs, by SARS-CoV-2 variants, and patient characteristics. 7. **METRICS** The primary evaluation metric is total hospital free days (HFD) at 28 days after mAB receipt calculated as 28 minus the number of days during the index stay minus the number of days readmitted during the 28 days after treatment. Death within 28 days is recorded as -1 HFD. Secondary evaluation metrics include: All-cause and all-location mortality at 28 and 90 days Emergency department visits at 28 days Organ-support free days at day 28 Where feasible: • SARS-CoV-2 nasopharyngeal and plasma viral loads among participants from baseline and longitudinally through day 28 • SARS-CoV-2 antibody titers, antibody neutralization, and other immune responses at baseline and longitudinally through day 28 • Detection of SARS-CoV-2 variants through next-generation sequencing at baseline and longitudinally through day 28 • Determining the duration of SAR-CoV-2 infectivity and non-culture surrogates for SARS-

CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding

8. **DESIGN**

839

840

846

848

- We will conduct a pragmatic evaluation of participants with COVID-19 illness under existing
- UPMC processes for the clinical care of COVID-19 positive patients, including EUA requirements
- for mAB administration. A patient who presents to a UPMC facility and tests positive for COVID-
- 844 19 will, as per current common care, be offered monoclonal antibodies. Data that are already
- collected according to UPMC procedures and EUA requirements are used for analysis.
- 847 9. POPULATION
- We will evaluate patients that present to UPMC Emergency Departments, urgent care sites,
- infusions centers and other facilities that can or do provide mABs for COVID-19. As of February
- 851 24, 2021, there are 3 EUAs, with common inclusion and exclusion criteria, and we will evaluate
- patients that meet these criteria. As other antibodies become available, we will modify this
- evaluation submission.
- 854 10. INCLUSION CRITERIA
- As per the current EUA criteria, the following patients are included:
- Adult (\geq 18 years old)
- Children > 12 years old weighing at least 40 kg
- With a positive SARS-CoV-2 antigen or PCR test and within 10 days of symptom onset
- High risk of disease progression
- High risk is defined as patients who meet at least one of the following criteria:
- A Body Mass Index (BMI) ≥ 35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are \geq 65 years old
- Are \geq 55 years of age AND have:
- o cardiovascular disease, OR
- o hypertension, OR

871 chronic obstructive pulmonary disease/other chronic respiratory disease 872 873 Are 12-17 years of age AND have: o BMI $\geq 85^{th}$ percentile for their age and gender based on CDC growth charts, OR 874 875 o sickle cell disease, OR 876 o congenital or acquired heart disease, OR 877 neurodevelopmental disorders (e.g., cerebral palsy), OR a medical-related technological dependence, for example, tracheostomy or 878 879 gastrostomy), OR 880 asthma, reactive airway, or other respiratory disease that requires daily medication 881 for control 882 11. **EXCLUSION CRITERIA** 883 884 As per the current EUA criteria, the following are excluded: 885 Are hospitalized for the treatment of COVID-19 886 Require oxygen therapy for the treatment of COVID-19 887 Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity 888 889 Have a known hypersensitivity to any antibody ingredient 890 **12. EVALUATED TREATMENTS** 891 892 Patients will receive COVID-19 mABs governed by FDA EUAs, when their treating physician 893 orders a mAB and they meet EUA criteria. Currently and under our examination, the treating 894 physician do not choose a specific mAB product. 895 As of February 24, 2021, there are three such mABs as listed below. 896 13. **BAMLANIVIMAB** 897 Bamlanivimab is a human immunoglobulin G-1 (IgG1 variant) monoclonal antibody consisting of 898 899 2 identical light chain polypeptides composed of 214 amino acids each and 2 identical heavy chain 900 polypeptides composed of 455 amino acids produced by a Chinese Hamster Ovary (CHO) cell line 901 and molecular weight of 146 kDa.

902 903 904 905 14. BAMLANIVIMAB and ETESVIMAB 906 907 Bamlanivimab is a human immunoglobulin G-1 (IgG1 variant) monoclonal antibody consisting of 908 2 identical light chain polypeptides composed of 214 amino acids each and 2 identical heavy chain 909 polypeptides composed of 455 amino acids produced by a Chinese Hamster Ovary (CHO) cell line 910 and molecular weight of 146 kDa. 911 Etesevimab is a human IgG1 variant monoclonal antibody (mAb) consisting of 2 identical light 912 chain polypeptides composed of 216 amino acids each and 2 identical heavy chain polypeptides 913 composed of 449 amino acids produced by a Chinese Hamster Ovary (CHO) cell line and 914 molecular weight of 145 kDa. 915 916 15. CASIRIVIMAB and IMDEVIMAB 917 918 Casirivimab, a human immunoglobulin G-1 (IgG1) monoclonal antibody (mAb), is covalent 919 eterotetramer consisting of 2 heavy chains and 2 light chains produced by recombinant DNA 920 technology in Chinese hamster ovary (CHO) cell suspension culture and has an approximate 921 molecular weight of 145.23 kDa. 922 Imdevimab, a human IgG1 mAb, is a covalent heterotetramer consisting of 2 heavy chains and 2 923 light chains produced by recombinant DNA technology in Chinese hamster ovary (CHO) cell 924 suspension culture and has an approximate molecular weight of 144.14 kDa. 925 926 CONCOMITANT THERAPY 16. 927 All care and concomitant therapy are as per the treating providers. 928 929 **17. CONDUCT** 930 931 18. DATA COLLECTION 932 933 The EUAs require that healthcare facilities and providers report therapeutic information and 934 utilization data through HHS Protect, Teletracking, or National Healthcare Safety Network as 935 directed by the US Department of Health and Human Services.

936 We will collect data including baseline demographics and underlying conditions, results of SARS-

937 COV-2 PCR or antibody testing, and initial care including mAB infusion completion. We will

938 collect post-randomization healthcare encounters, including hospitalization, emergency

department visits, ICU care, and other measures of healthcare utilization. We will use an electronic

health record data collection process to augment existing UPMC data collection processes as

941 necessary.

939

940

953

958

962

963 964

- All data will be handled and secured as per University of Pittsburgh and UPMC data guidelines.
- There will be no research activities involving direct interaction with subjects performed as part of
- 944 this evaluation.
- In addition to the primary and secondary outcome data referenced in this submission, data collected
- 946 will include the below areas. All data will be abstracted directly from the electronic health record
- and handled anonymously.
- Which mAB was administered, including date, time, and infusion completion as well as
- 949 the location of the infusion
- Demographics (including age, sex, race, body weight, vaccination status)
- Healthcare encounters, including hospital and ICU admission status if applicable
- Medication usage and doses
 - Hospital and ICU admission status, if applicable
- Administration of medications related to COVID-19, if applicable
- Remnant blood availability
- Laboratory and microbiology data, including COVID-19 testing done for clinical purposes

957 19. BIOSPECIMENS

- Where feasible, we will collect discarded remnant blood samples and nasal/oropharyngeal swab
- samples to quantify the viral load and host response to the virus. As noted under data collection,
- 961 we will record laboratory and microbiology data performed for clinical purposes.

20. ANTIBODY ADMINISTRATION

- Antibodies will be administered as per the EUAs and UPMC Pharmacy and Therapeutics policies.
- 966 Providers will explain mAB risks and benefits and provide the EUA Fact Sheets for Patients,

967 Parents and Caregivers

- as per EUA requirements.
- 969 21. mAB assignment

970

- 971 The COVID-19 mABs are currently routinely used at UPMC. Once any order for mAB infusion
- 972 is approved by the UPMC system oversight group, the pharmacy provides whichever EUA-
- 973 governed mAB is available under a therapeutic interchange approach. Ordering physicians review
- 974 with the patient the EUA Fact Sheet for each mAB and explain that the patient could receive any
- of the mABs governed by FDA EUAs.
- 976 If demand for mAB exceeds supply, UPMC has a lottery system to allot who receives the therapy
- once requested by a physician.
- 978 Our current proposal is a UPMC system quality improvement initiative, embracing and extending
- 979 the current lottery system and therapeutic interchange policy for EUA-governed mABs for
- 980 COVID-19 as follows:
- 981 1. The Physician orders mAB.
- a. If scarcity present and lottery system allow provision, proceed.
- 2. The Pharmacy fills order with one of the EUA-governed COVID-19 mABs using an embedded
- 984 assignment system akin to current mAb provision. This system will allow a comparative
- 985 effectiveness evaluation of the multiple mABs by effectively ensuring random allocation.
- 986 3. The Physician can agree to the assigned mAB or can request a specific mAB.
- 987 It is the treating physician's choice to accept the assigned mAB or not, and therefore patient
- 988 consent for the mAB assignment is not required. Patients will be told which mAB they are
- 989 receiving, along with an EUA Fact Sheet, as per EUA requirements.

22. STATISTICAL CONSIDERATIONS

994 23. STRATA

990

991

992

993

- 996 Predefined strata will include patients discharged home after infusion, patients admitted to hospital
- 997 after infusion, prior vaccination, and if known, presence of virus variants of concern at baseline
- and presence of neutralizing antibodies to SARS-CoV-2 at baseline.

24. NUMBER of PARTICIPANTS

- Sample size is determined by case volume throughout the course of the pandemic.
- 1002 25. STATISTICAL ANALYSIS

999

1000

1003

1010

1012

1021

- The primary evaluation metric is the number of days free from hospitalization to day 28. We will
- finalize a statistical analysis plan which will consider mAB assignment, heterogeneity of treatment
- 1006 effect by patient characteristics and virus variants, and interaction with other treatments. Due to
- uncertainty in sample size, we will use a Bayesian adaptive design to ensure ability to provide
- statistical inference despite variable sample size.

1009 26. ETHICAL CONSIDERATIONS

- 1011 27. DATA MONITORING
- 1013 Evaluation center leadership will regularly monitor monthly reports on enrollment, patient
- 1014 characteristics, and outcomes.
- 1015 28. CONSENT
- As per EUA requirements, physicians will discuss the risks and benefits of mABs and patients will
- 1017 consent to receive a mAB as part of usual care, should they desire mAB treatment. As per UPMC
- policy, the ordering physician reviews with patients the EUA Fact Sheet for each mAB and explain
- that the patient could receive any of the mABs governed by FDA EUAs.
- 1020 29. ADVERSE EVENTS and SERIOUS ADVERSE EVENTS
- The EUAs require providers and/or their designees report all medication errors and serious adverse
- events potentially related to the antibodies within seven calendar days from the onset of the event.
- Serious adverse events are defined as death, life-threatening event, inpatient hospitalization or
- prolongation of existing hospitalization, substantial disruption of ability to conduct normal life
- functions, a congenital anomaly/birth defect, or an intervention to prevent death, a life-threatening
- event, hospitalization, disability, or congenital anomaly.
- 1028 The EUAs require adverse event reports be submitted to FDA MedWatch via one of multiple
- methods. Copies of all FDA MedWatch forms are also to be sent to the antibody manufacturer.

1030 Thus, there already exist reporting requirements for UPMC associated with mAB prescription. We 1031 will track and record these reported data and adverse events by mAB assignment. 1032 30. SAFETY and RISK MITIGATION 1033 1034 The EUAs stipulate warnings including hypersensitivity, clinical worsening, and side effects. As 1035 per EUA requirements, warnings will be communicated by providers to patients, adverse events 1036 will be reported as above, and post-infusion clinical monitoring will be done. Administration of 1037 mABs for patients with COVID-19 is routine care at UPMC, and their administration is not a 1038 research procedure. MANAGEMENT of INFUSION REACTIONS 1039 31. 1040 As per the EUAs, all participants should be monitored closely, as there is a risk of infusion reaction and hypersensitivity (including anaphylaxis) with any biological agent. Symptoms and signs that 1041 1042 may occur as part of an infusion reaction include, but are not limited to fever, chills, nausea, 1043 headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, 1044 pruritus, myalgia, and dizziness. 1045 **32. EXHIBITS** 1046 1047 EUA fact sheets for health care providers 1048 https://www.fda.gov/media/143603/download https://www.fda.gov/media/143892/download 1049 https://www.fda.gov/media/145802/download 1050 1051 1052 1053 1054 1055 1056 1057

FINAL VERSION 1.3, June 30, 2021

UPMC OPTIMISE-C19 (<u>OP</u>timizing <u>T</u>reatment and <u>I</u>mpact of <u>M</u>onoclonal ant<u>I</u>bodie<u>S</u> through <u>E</u>valuation for COVID-19)

A pragmatic evaluation of monoclonal antibody treatments in participants with COVID-19 illness (ClinicalTrials.gov, NCT04790786)

Summary	
Background	 FDA Emergency Use Authorization (EUA) exists for multiple monoclonal antibodies (mAB) to treat COVID-19; the EUAs stipulate eligibility criteria, patient-physician communication, and clinical monitoring.¹ UPMC provides mABs as routine care; physicians order a mAB infusion and pharmacies assign whichever mAB is available under a therapeutic interchange approach. If scarcity exists, a lottery system is used. Physicians review with patients the EUA Fact Sheet for each mAB and explain they could be assigned any of the EUA-governed mABs.²⁻
Approach	 Structure the therapeutic interchange policy and lottery system using a UPMC pharmacy embedded assignment system that allows a comparative effectiveness evaluation of the multiple mABs.⁵ Collect data from clinically performed UPMC processes and EUA requirements for routine care.
Treatments	 Monoclonal antibodies (mAB) for COVID-19
Inclusion Criteria	These criteria are as per the FDA EUAs for COVID-19 mABs as of June 2021. ⁶ • Adult (≥ 18 years old)
	 Children ≥ 12 years old weighing at least 40 kg
	• With a positive SARS-CoV-2 antigen or PCR test and within 10 days
	of symptom onset
	High risk of disease progression
	High risk is defined as patients who meet at least one of the following criteria:
	 Are ≥ 65 years old
	• A Body Mass Index (BMI)>25, or if age 12-17, BMI > 85 th percentile
	• Pregnancy
	Have chronic kidney disease
	Have diabetes
	Have immunosuppressive disease

	Are currently receiving immunosuppressive treatment		
	Cardiovascular disease (including congenital heart disease) or		
	hypertension		
	Chronic lung disease		
	sickle cell disease		
	neurodevelopmental disorders (e.g., cerebral palsy) or other conditions		
	that confer medical complexity (e.g., genetic, or metabolic syndromes		
	and severe congenital anomalies)		
	• a medical-related technological dependence, for example,		
	tracheostomy or gastrostomy)		
	The EUAs note that other medical conditions or factors (for example, race or		
	ethnicity) may also place individual patients at high risk for progression and		
	authorization of mAB treatment under the EUA is not limited to the medical		
	conditions or factors listed above.		
Exclusion Criteria	These criteria are as per the FDA EUAs for COVID-19 mABs as of April 2021. ⁶		
Cincina	2021.		
	 Are hospitalized for the treatment of COVID-19 Require oxygen therapy for the treatment of COVID-19 		
	 Require oxygen therapy for the treatment of COVID-19 Require an increase in baseline oxygen flow rate due to COVID-19 in 		
	those on chronic oxygen therapy due to underlying non-COVID-19		
	related comorbidityHave a known hypersensitivity to any antibody ingredient		
Primary	Total hospital free days at 28 days		
evaluation			
metric			

Table of Contents 1068 1069 1070 BACKGROUND and RATIONALE65 2.1. BACKGROUND.......65 1071 1072 2.2. RATIONALE 66 3. OBJECTIVES AND METRICS.......67 1073 3.1. 1074 1075 3.2. 1076 POPULATION 68 1077 1078 4.1.1. **INCLUSION CRITERIA** 68 4.1.2. **EXCLUSION CRITERIA** 69 1079 1080 5.1. 1081 1082 5.2. 5.3. 1083 1084 6.1. 1085 6.2. 1086 6.3. ANTIBODY ADMINISTRATION71 1087 1088 6.4. 1089 7.1. 1090 7.2. 1091 7.3. 1092 1093 8.1. 1094 1095 8.2. 8.3. ADVERSE EVENTS and SERIOUS ADVERSE EVENTS.......73 1096 8.3.1. 1097 SAFETY and RISK MITIGATION 74 MANAGEMENT of INFUSION REACTIONS 74 1098 8.3.2. 1099 1100

1. ABBREVIATIONS

AE	Adverse Events
BMI	
	Body Mass Index
C + I	casirivimab + imdevimab
CDC	Centers for Disease Control and Prevention
COPD	Chronic Obstructive Pulmonary Disease
COVID-19	Coronavirus disease 2019
CVD	Cardiovascular Disease
EUA	Emergency Use Authorization
FDA	Food and Drug Administration
HHS	Health and Human Services
HFD	Hospital Free Days
HTN	Hypertension
kDa	Kilodaltons
IgG1	Immunoglobulin G1
KG	Kilograms
OPTIMISE-	OP timizing T reatment and I mpact of
C19	Monoclonal ant Ibodie S through Evaluation
mAB	Monoclonal Antibodies
PCR	Polymerase Chain Reaction
SAEs	Serious Adverse Events
SARS-CoV-	Severe Acute Respiratory Syndrome
2	Coronavirus 2
UATRC	UPMC Antibody Treatment and Evaluation
	Center
Vir-7831	sotrovimab

2. BACKGROUND and RATIONALE

3. BACKGROUND

While COVID-19 vaccination will reduce COVID-19-related morbidity and mortality, the learned immune response may vary between individuals. This means interventions such as monoclonal antibodies (mAB) will still be needed to prevent progression of COVID-19 illness. Monoclonal antibodies seek to mimic or enhance the natural immune system response against a pathogen and are often used in the care of patients with cancer or infection.

1114 For viral infections, mABs are created by exposing a white blood cell to a particular viral protein, 1115 which is then cloned to mass produce antibodies to target that virus. For SARS-CoV-2, the virus 1116 that causes COVID-19, IgG1 mABs target the spike protein of SARS-CoV-2 and block viral 1117 attachment and entry into cells. 1118 The SARS-CoV-2 mABs bamlanivimab and etesevimab, and the REGN-COV2 combination 1119 (casirivimab + imdevimab) reduce nasopharyngeal viral burden plus clinical outcomes including future emergency department visits and hospitalizations (Weinreich 33332778 NEJM, Gottlieb 1120 1121 33475701). Each received FDA Emergency Use Authorization (EUA) for use in selected 1122 populations (Exhibit); in April 2021 FDA revoked the EUA for bamlanivimab monotherapy, and in June 2021 FDA recommended bamlanivimab and etesevimab not be used. Additional trials of 1123 pre-exposure prophylaxis (NCT04497987) and other applications are underway, and additional 1124 1125 mABs are in development. In May 2021, it was announced that sotroyimab demonstrated clinical efficacy (85%) in reducing 1126 1127 hospitalizations for more than 24 hours or death in those that received sotrovimab as compared to placebo (NCT04545060). Subsequently, it received EUA approval in select populations. 1128 1129 Additional trials are underway. 1130 The trials demonstrated the greatest impact of the REGN-COV2 dual therapy among patients who 1131 lacked neutralizing antibodies against SARS-CoV-2 at baseline and in those with high 1132 nasopharyngeal viral loads. Additionally, few patients in the bamlanivimab/etesevimab trial 1133 developed treatment-emergent SARS-CoV-2 resistance. This latter phenomenon may further 1134 enhance the need for therapies given the recent emergence of SARS-CoV-2 variants that may 1135 escape vaccination. However, the relative effectiveness of each mAB compared to the other is 1136 unknown, as is their effectiveness for emerging virus variants. 1137 This Appendix to the UPMC Pilot Core (PittPro 20040210) describes the approach of the UPMC 1138 OPTIMISE-C19 evaluation. We will conduct a pragmatic evaluation of monoclonal antibody 1139 treatments in participants with COVID-19 illness, starting with the patient population approved 1140 under the current FDA mAB EUAs.

4. RATIONALE

1141

1142

1143

1144

1145

As of June 2021, there are over 10,000 new cases of COVID-19 diagnosed daily in the US https://covid.cdc.gov/covid-data-tracker/#trends dailytrendscases, with over 1500 daily COVID-

- 19 related hospital admissions Microsoft Power BI (powerbigov.us). Although case volumes are
- currently declining, COVID-19 remains a significant public health threat.
- Despite the EUAs, the clinical use of mABs is low due in part to lack of patient access,
- complexities in drug allocation, and lack of knowledge among providers are contributing factors.
- Further, the comparative effectiveness of different mABs is unknown and not yet directly studied.
- 1151 The National Academies of Sciences, Engineering, and Medicine recently called for expanded
- access and clinical use of mABs, noting it is "critical to collect data and evaluate whether they are
- 1153 working as predicted".

1158

1160

1166

- 1154 This evaluation seeks to expand access to mABs at UPMC and determine their relative effects
- versus each other, starting with those governed by EUAs.

1157 5. OBJECTIVES AND METRICS

1159 6. OBJECTIVES

- The primary objective is to evaluate the clinical and biological effect of multiple monoclonal
- antibodies (mABs) in patients with COVID-19.
- 1163 The primary hypothesis is clinical and biological effect will vary between mABs, by SARS-CoV-
- 2 variants, and patient characteristics.
- 1165 7. METRICS
- The primary evaluation metric is total hospital free days (HFD) at 28 days after mAB receipt
- calculated as 28 minus the number of days during the index stay minus the number of days
- readmitted during the 28 days after treatment. Death within 28 days is recorded as -1 HFD.
- 1170 Secondary evaluation metrics include:
- All-cause and all-location mortality at 28 and 90 days
- Emergency department visits at 28 days
- Organ-support free days at day 28
- Where feasible:
- SARS-CoV-2 nasopharyngeal and plasma viral loads among participants from baseline and
- longitudinally through day 28

- SARS-CoV-2 antibody titers, antibody neutralization, and other immune responses at baseline and longitudinally through day 28
- Detection of SARS-CoV-2 variants through next-generation sequencing at baseline and
 longitudinally through day 28
- Determining the duration of SAR-CoV-2 infectivity and non-culture surrogates for SARS CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding

8. **DESIGN**

1183

1184

1185

1191

1193

1199

1200

- We will conduct a pragmatic evaluation of participants with COVID-19 illness under existing
- 1187 UPMC processes for the clinical care of COVID-19 positive patients, including EUA requirements
- 1188 for mAB administration. A patient who presents to a UPMC facility and tests positive for COVID-
- 1189 19 will, as per current common care, be offered monoclonal antibodies. Data that are already
- 1190 collected according to UPMC procedures and EUA requirements are used for analysis.

1192 9. POPULATION

- We will evaluate patients that present to UPMC Emergency Departments, urgent care sites,
- infusions centers and other facilities that can or do provide mABs for COVID-19. As of June 30,
- 2021, there are 2 EUAs for COVID-19 mABs, with common inclusion and exclusion criteria, and
- we will evaluate patients that meet these criteria. As FDA antibody decisions change (E.g., FDA)
- revokes or grants EUAs, or changes eligibility criteria), eligibility criteria will change.

10. INCLUSION CRITERIA

- 1201 As per the current EUA criteria (June 2021), the following patients are included:
- Adult (> 18 years old)
- Children > 12 years old weighing at least 40 kg
- With a positive SARS-CoV-2 antigen or PCR test and within 10 days of symptom onset
- High risk of disease progression
- High risk is defined as patients who meet at least one of the following criteria:
- Are \geq 65 years old

A Body Mass Index (BMI)>25, or if age 12-17, BMI > 85th percentile 1208 1209 Pregnancy 1210 Have chronic kidney disease 1211 Have diabetes Have immunosuppressive disease 1212 1213 Are currently receiving immunosuppressive treatment Cardiovascular disease (including congenital heart disease) or hypertension 1214 Chronic lung disease 1215 sickle cell disease 1216 neurodevelopmental disorders (e.g., cerebral palsy) or other conditions that confer medical 1217 1218 complexity (e.g., genetic, or metabolic syndromes and severe congenital anomalies) 1219 a medical-related technological dependence, for example, tracheostomy or gastrostomy) 1220 The EUAs note that other medical conditions or factors (for example, race or ethnicity) may also 1221 place individual patients at high risk for progression and authorization of mAB treatment under the EUA is not limited to the medical conditions or factors listed above. 1222 1223 11. **EXCLUSION CRITERIA** 1224 1225 As per the current EUA criteria (June 2021), the following are excluded: Are hospitalized for the treatment of COVID-19 1226 1227 Require oxygen therapy for the treatment of COVID-19 1228 Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic 1229 oxygen therapy due to underlying non-COVID-19 related comorbidity 1230 Have a known hypersensitivity to any antibody ingredient 1231 **12. EVALUATED TREATMENTS** 1232 1233 We will evaluate mABs governed by FDA EUAs. Patients will receive COVID-19 mABs 1234 governed by FDA EUAs, when their treating physician orders a mAB and they meet EUA criteria. 1235 As FDA antibody decisions change (E.g., FDA revokes or grants EUAs, provides full approval, or 1236 changes eligibility criteria), available evaluated treatments will change. In April 2021, FDA 1237 revoked the EUA for bamlanivimab monotherapy and in June 2021 FDA recommended

1238

bamlanivimab and etesevimab not be used.

- As of June 30, 2021, the EUA-approved mABs are as listed below.
- 1240 13. CASIRIVIMAB and IMDEVIMAB
- 1242 Casirivimab, a human immunoglobulin G-1 (IgG1) monoclonal antibody (mAb), is covalent
- 1243 eterotetramer consisting of 2 heavy chains and 2 light chains produced by recombinant DNA
- technology in Chinese hamster ovary (CHO) cell suspension culture and has an approximate
- molecular weight of 145.23 kDa.
- 1246 Imdevimab, a human IgG1 mAb, is a covalent heterotetramer consisting of 2 heavy chains and 2
- light chains produced by recombinant DNA technology in Chinese hamster ovary (CHO) cell
- suspension culture and has an approximate molecular weight of 144.14 kDa.
- 1249 14. SOTROVIMAB

1250

1254

1257

1259

- 1251 Vir 7831 (sotrovimab) is a recombinant human IgG1k monoclonal antibody that binds to a
- 1252 conserved epitope on the spike protein receptor binding domain of SARS-CoV-2. Sotrovimab does
- not compete with human ACE2 receptor binding.
- 1255 15. CONCOMITANT THERAPY
- All care and concomitant therapy are as per the treating providers.
- 1258 **16. CONDUCT**
- 1260 17. DATA COLLECTION
- 1262 The EUAs require that healthcare facilities and providers report therapeutic information and
- 1263 utilization data through HHS Protect, Teletracking, or National Healthcare Safety Network as
- directed by the US Department of Health and Human Services.
- We will collect data including baseline demographics and underlying conditions, results of SARS-
- 1266 COV-2 PCR or antibody testing, and initial care including mAB infusion completion. We will
- 1267 collect post-randomization healthcare encounters, including hospitalization, emergency
- department visits, ICU care, and other measures of healthcare utilization. We will use an electronic
- health record data collection process to augment existing UPMC data collection processes as
- necessary.

- 1271 All data will be handled and secured as per University of Pittsburgh and UPMC data guidelines.
- There will be no research activities involving direct interaction with subjects performed as part of
- this evaluation.
- 1274 In addition to the primary and secondary outcome data referenced in this submission, data collected
- will include the below areas. All data will be abstracted directly from the electronic health record
- and handled anonymously.
- mAB was administered, including date, time, and infusion completion as well as the
- 1278 location of the infusion
- Demographics (including age, sex, race, body weight, vaccination status)
- Healthcare encounters, including hospital and ICU admission status if applicable
- Medication usage and doses
- Hospital and ICU admission status, if applicable
- Administration of medications related to COVID-19, if applicable
- Remnant blood availability
- Laboratory and microbiology data, including COVID-19 testing done for clinical purposes
- 1286 18. BIOSPECIMENS

1291

1293

- Where feasible, we will collect discarded remnant blood samples and nasal/oropharyngeal swab
- samples to quantify the viral load and host response to the virus. As noted under data collection,
- we will record laboratory and microbiology data performed for clinical purposes.
- 1292 19. ANTIBODY ADMINISTRATION
- 1294 Antibodies will be administered as per the EUAs, UPMC Pharmacy and Therapeutics policies and
- the respective Pharmacy Manuals (as generated by the pharmaceutical companies), if applicable.
- Providers will explain mAB risks and benefits and provide the EUA Fact Sheets for Patients,
- 1297 Parents and Caregivers
- as per EUA requirements.
- 1299 20. mAB assignment
- 1301 The COVID-19 mABs are currently routinely used at UPMC. Once any order for mAB infusion
- is approved by the UPMC system oversight group, the pharmacy provides whichever EUA-
- governed mAB is available under a therapeutic interchange approach. Ordering physicians review

- with the patient the EUA Fact Sheet for each mAB and explain that the patient could receive any
- of the mABs governed by FDA EUAs.
- 1306 If demand for mAB exceeds supply, UPMC has a lottery system to allot who receives the therapy
- once requested by a physician.
- Our current proposal is a UPMC system quality improvement initiative, embracing and extending
- the current lottery system and therapeutic interchange policy for EUA-governed mABs for
- 1310 COVID-19 as follows:
- 1311 1. The Physician orders mAB.
- a. If scarcity present and lottery system allow provision, proceed.
- 2. The Pharmacy fills order with one of the EUA-governed COVID-19 mABs using an embedded
- assignment system akin to current mAb provision. This system will allow a comparative
- effectiveness evaluation of the multiple mABs by effectively ensuring random allocation.
- 1316 3. The Physician can agree to the assigned mAB or can request a specific mAB.
- 1317 It is the treating physician's choice to accept the assigned mAB or not, and therefore patient
- consent for the mAB assignment is not required. Patients will be told which mAB they are
- receiving, along with an EUA Fact Sheet, as per EUA requirements.

1323 21. STATISTICAL CONSIDERATIONS

1325 22. STRATA

1320

1321

1322

1324

1326

1331

- Predefined strata will include patients discharged home after infusion, patients admitted to hospital
- after infusion, prior vaccination, and if known, presence of virus variants of concern at baseline
- and presence of neutralizing antibodies to SARS-CoV-2 at baseline.
- 1330 23. NUMBER of PARTICIPANTS
- Sample size is determined by case volume throughout the course of the pandemic.
- 1333 24. STATISTICAL ANALYSIS

1335

1336

1337

1338

1339

1340

13411342

1343

1344

1345

1346

1347

1348

1349

1350

1351

1352

1353 1354

1355

1356

1357

1358

1359

1360

1361

1362

1363

The primary evaluation metric is the number of days free from hospitalization to day 28. We will finalize a statistical analysis plan which will consider mAB assignment, heterogeneity of treatment effect by patient characteristics and virus variants, and interaction with other treatments. Due to uncertainty in sample size, we will use a Bayesian adaptive design to ensure ability to provide statistical inference despite variable sample size. 25. ETHICAL CONSIDERATIONS 26. **DATA MONITORING** UPMC clinical leadership will regularly monitor monthly reports on enrollment, patient characteristics, and outcomes. Leadership will also receive regular interim analyses from the adaptive statistical model to inform UPMC clinical policy. 27. **CONSENT** As per EUA requirements, physicians will discuss the risks and benefits of mABs and patients will consent to receive a mAB as part of usual care, should they desire mAB treatment. As per UPMC policy, the ordering physician reviews with patients the EUA Fact Sheet for each mAB and explain that the patient could receive any of the mABs governed by FDA EUAs. 28. ADVERSE EVENTS and SERIOUS ADVERSE EVENTS The EUAs require providers and/or their designees report all medication errors and serious adverse events potentially related to the antibodies within seven calendar days from the onset of the event. Serious adverse events are defined as death, life-threatening event, inpatient hospitalization or prolongation of existing hospitalization, substantial disruption of ability to conduct normal life functions, a congenital anomaly/birth defect, or an intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly. The EUAs require adverse event reports be submitted to FDA MedWatch via one of multiple methods. Copies of all FDA MedWatch forms are also to be sent to the antibody manufacturer. Thus, there already exist reporting requirements for UPMC associated with mAB prescription. We will track and record these reported data and adverse events by mAB assignment.

1364 29. SAFETY and RISK MITIGATION 1365 The EUAs stipulate warnings including hypersensitivity, clinical worsening, and side effects. As 1366 per EUA requirements, warnings will be communicated by providers to patients, adverse events 1367 will be reported as above, and post-infusion clinical monitoring will be done. Administration of 1368 1369 mABs for patients with COVID-19 is routine care at UPMC, and their administration is not a 1370 research procedure. MANAGEMENT of INFUSION REACTIONS 1371 30. 1372 As per the EUAs, all participants should be monitored closely, as there is a risk of infusion reaction 1373 and hypersensitivity (including anaphylaxis) with any biological agent. Symptoms and signs that 1374 may occur as part of an infusion reaction include, but are not limited to fever, chills, nausea, 1375 headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, 1376 pruritus, myalgia, and dizziness. 31. **EXHIBITS** 1377 1378 1379 EUA fact sheets for health care providers 1380 1381 https://www.fda.gov/media/149534/download (sotrovimab) 1382 https://www.regeneron.com/downloads/treatment-covid19-eua-fact-sheet-for-hcp.pdf 1383 (casirivimab and imdevimab) 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393

SUMMARY OF CHANGES

OPTIMISE-C19 - Summary of Changes for Amendment 1 on April 25, 2021:

Page #	Protocol Section	Reason for Change	
1	Protocol Title Page	Title Changed to reflect new abbreviation being used for	
		study	
2-3	Summary table	Summary table updated to reflect protocol changes	
10	4.1	Clarification added to section 4.1 to reflect changing	
		landscape of FDA EUA authorization and revocation	
12	5	Clarification added to section 5 to reflect changing	
		landscape of FDA EUA authorization and revocation	
12	5.1	Removed Section 5.1 Bamlanivimab due to EUA being	
		revoked by the FDA	
17	8.1	Updated to provide more detail on the monitoring of data	
		by UPMC clinical leadership	
18	9	EUA for Bamlanivimab removed	

Page #	Protocol Section	Reason for Change	
NA	NA	Minor administrative changes throughout the	
		document to reflect Amendment #2 documentation	
2-3	Summary table	Summary table updated to reflect protocol changes	
7	2.1.	Information regarding new monoclonal antibody	
7	2.1.	Information added regarding the revocation of EUA	
		approved of bamlanivimab and etesvimab	
8	2.2.	Information added to reflect current COVID trends	
10-11	4.1.1.	Updated Inclusion Criteria as per EUA requirements	
12	5	Information added regarding the revocation of EUA	
		approved of Bamlanivimab	
12	5.1.	Removal of section 5.1. – bamlanivimab and etesvimab	
12-13	5.2.	Addition of newly approved monoclonal antibody –	
15	6.3.	Information added to reflect UPMC will utilize a	
		pharmacy manual if provided by the drug	
19	9.0.	Exhibits added and removed to reflect current EUA	
		approved monoclonal antibodies	

OPTIMISE-C19 - Summary of Changes for Amendment 2 on June 30, 2021:

1410 STATISTICAL ANALYSIS PLAN 1411 1412 1. Introduction 1413 This document describes the detail of the analysis read-out from July 26, 2021. This document is 1414 an appendix to the Statistical Analysis Plan for the "UPMC Antibody Treatment and Evaluation Center" with the details for this analysis read-out. 1415 1416 1417 We will analyze and report three treatment arms (below) as the first two have been administratively closed to enrollment due to FDA decisions. 1418 1419 1420 Unblinded data from this and prior interim analyses can be shared with investigators after 1421 the last randomized allocations (June 25) to the two mAB treatment arms closed by FDA. 1422 1423 This unblinding is appropriate as future analyses of patients randomized to the third arm (C+I) will not be compared to the first two arms, there are no "control" arms as all 1424 patients receive mAB treatment, and future comparisons will be of C+I vs newer mABs. 1425 1426 1427 Enrollment continues in the currently available treatment arms (C+I and S). "S" refers to 1428 sotrovimab, produced by GSK and Vir. 1429 2. **Treatment Arms** There are three treatment arms that will be included in this analysis. The treatment arms are 1430 1431 1. B (Bamlanivimab) 2. B+E (Bamlaniviman/Etesevimab combination) 1432 1433 3. C+I (casirivimab/imdevimab combination) 1434 **3. Primary Endpoint** The primary endpoint for this read-out is hospital-free days. 1435 1436 4. **Primary Analysis Population** The primary analysis population for this read-out is the "As-Infused" population. This analysis 1437 1438 will include each patient randomized from March 10, 2021 until June 25, 2021. The date of the 1439 data set snapshot is on July 26, 2021. 5. 1440 **Primary Analysis Model** The primary analysis model is as described in the trial SAP. 1441 1442 1443 The primary analysis for the primary endpoint is a cumulative proportional odds model. Let the 1444 probability of an outcome of less than or equal to y be $\pi_v = Pr(Y \le y)$. Let a be the indicator of treatment arm (a=1,...,k). The model adjusts for the following baseline variables: 1445

- 1. ED or infusion center (0=infusion center, 1=ED)
 - 2. Age (with categories of <30, 30-39, 40-49, 50-59, 60-69, 70-79, and \ge 80; 60-69 will be used as the referent)
 - 3. Sex (sex at birth, male is the referent)

- 4. Covid variant is not modeled in this primary analysis
- 5. Time (two-week epochs of time are used for adjustments; the most current 4-week period is the referent)

1454 The primary analysis model is based on a cumulative logistic regression, where $\pi_y = \Pr(Y \le y)$, where

$$\log\left(\frac{\pi_{y}}{1-\pi_{v}}\right) = \alpha_{y} - \theta_{a}\delta_{[a]} - \sum_{v=1}^{4} \beta_{vj}\delta_{vj} - \lambda_{[time]}; \ y = -1,0,1,2,...27.$$

The additive covariate effects across all treatment arms for each patient are modeled through the β parameters. The δ parameters are indicator functions for the treatment arm and covariate values for the baseline covariates. The efficacy of the treatment arms is modeled with the θ parameters. The ordinal effect parameters (α_y) are modeled with a Dirichlet distribution with equal weight on each outcome and a sum of 1.

The baseline covariate effects are modeled with independent weak prior distributions:

$$\beta_{vj} \sim N(0,10^2), v = 1, ..., 4; j = 1, ..., n_v.$$

The appropriate coefficients will be set to 0 within each covariate for identifiability (the goal will be the largest category set to 0).

The effects of time are adjusted within the model using two-week epochs and a smoothing model over time. The modeling of the time effects is set up with the most current period (2 epochs combined being the most recent month are set to 0):

$$\lambda_1 \equiv \lambda_2 \equiv 0$$

$$\lambda_2 - \lambda_1 \sim N(0, 0.15^2)$$

$$\lambda_T - 2\lambda_{T-1} + \lambda_{T-2} \sim N(0, \tau_\lambda^2); T \ge 3$$

$$\tau_\lambda^2 \sim IG(0.25, 0.00562)$$

The prior distributions for the mAB treatment effects are weak:

$$\theta_a \sim N(0.10), a = 1.2.3.$$

- 6. The treatment arms with the largest sample size should be selected as the referent arm (label a=1)_for treatment effects and assigned a treatment effect of $\theta_1 = 0$.
- 7. Model Convergence

- 1490 Given the complexity of the model, conventions may be taken by the analysis team if there are
- 1491 convergence issues or model stability issues. For example, there may be outcome categories in
- the 30 possible primary outcome values (e.g., k number of hospital-free days, patient death) that
- do not occur. If this happens at analysis, the cells will be combined to achieve model
- 1494 convergence. For example, if the 4 hospital-free day outcome value does not occur it will be
- 1495 combined with 3, and so on, until every cell has occurred. Additional model stability conventions
- will be taken to preserve the model stability.

8. Missing and Partial Data

1497

1498

1499

1500

1501

1502 1503

1504

1505

1506

1511

15121513

1514

1515

1516

1517 1518 1519

1520

1521 1522

15231524

1525

1526

1527

1528 1529

1530

1531

If there are missing covariates for a patient in the as-infused patient population, the following conventions will be used.

- 1. If the treatment arm is missing the patient will be ignored.
- 2. If a baseline covariate is missing the referent value for that covariate will be used

For all model analyses, only patients who have achieved 28-days of follow-up from the date of the index infusion will be used in the analysis. No use or imputation of patient data for patients with less than 28 days will be conducted.

- 1507 Given the HER-based data summaries there will be no missing outcome data. If there is deemed
- to be a corrupted outcome that patient will be ignored. Some patients may have 28
- hospitalization-free days that at subsequent analyses are found to have out of system
- hospitalizations. The data will be updated at future analyses.

9. Trial Inferences

For the primary analysis, there is no "control" treatment and so all inferences are made comparing the individual treatment arms to each other. The main quantity of interest will be the relative odds ratio between any two treatments arms

$$OR_{ij} = \exp(\theta_i)/\exp(\theta_j).$$

The posterior probability that the odds ratio for arm *i* compared to arm *j* is greater than 1 (signifying that treatment *i* is superior to treatment *j*) is used as a comparison between arms. Additionally, the posterior mean and 95% confidence interval between arms will be used to summarize relative treatment effects.

Arm Inferiority: If one of the arms has a 99% chance of being inferior to any of the other available arms then the inferior arm will be declared inferior and may be removed from the trial. There may be conditions of the pandemic (variation frequency, new variations) or drug supply concerns that an arm is retained.

Equivalence: Any two arms in the trial may reach a declaration of equivalence. It is anticipated that no actions would take when equivalence is reached but a declaration and public disclosure may be made. There is a sliding scale of equivalence with different levels of equivalence bounds.

A declaration of equivalence will be tied to the equivalence level. Equivalence with a bound of d is declared if the posterior probability of the odds ratio is with d is at least 95%:

$$\Pr\left(\frac{1}{1+\delta} \le OR_{ij} \le 1+\delta\right) \ge 0.95$$

The following levels are pre-defined:

- 1. The first level of equivalence occurs when there is 95% posterior probability that the odds-ratio is within a bound of d=0.25
- 2. The second level of equivalence occurs when there is a 95% posterior probability that the odds-ratio is within a bound of d=0.20
- 3. The third level of equivalence occurs when there is a 95% posterior probability that the odds-ratio is within a bound of d=0.15
- 4. The fourth level of equivalence occurs when there is a 95% posterior probability that the odds-ratio is within a bound of d=0.10
- 5. The fifth level of equivalence occurs when there is a 95% posterior probability that the odds-ratio is within a bound of d=0.05

Combination Futility: For comparing B+E to B the combination (B+E) will be compared to the individual component arm (B). If there is more than a 95% probability that the effect of the combination B+E is no better than a 20% improvement in the odds ratio compared to B, then the combination will be declared *not clinically relevantly superior (combination futile)* to N.

10. Modeling Treatment Heterogeneity Across Variant Date Prevalence Epochs

For this read out, the following time epochs will be modeled with different treatment effects using the Treatment Heterogeneity analysis model.

The treatment effect, θ_a , will be modeled separately within each epoch, s = 1, ..., S, as $\theta_{a1}, \theta_{a2}, ..., \theta_{aS}$, with hierarchical prior distribution:

$$\theta_{as} \sim N(\mu_a, \tau_a^2), a = 1, ..., 3; s = 1, ..., S.$$

$$\mu_a{\sim}N(0{,}10^2);\tau_a^2{\sim}IG(0.25,0.1).$$

The following time epochs are specified:

- 1. March 10 March 31
- 2. April 1 April 30
- 3. May 1 May 31
- 4. June 1 June 25

Specific Analyses

# Status Population Endpoint Other	
------------------------------------	--

1	Primary	As-Infused to B, B+I, or C+I on or before June 25, 2021	HFD	
2	Variant Secondary	As-Infused to B, B+I, or C+I on or before June 25, 2021	HFD	Differential efficacy by time epoch specified

The primary analysis

 The following posterior probabilities will be reported

Quantity of Interest	Posterior Probability
B+E superior to B	
B+E combination futile to B	
C+I superior to B	
C+I superior to B+E	

Statistical Triggers Met for Equivalence with delta ranges of equivalence.

The following will be reported:

Odds-Ratio	Mean	SD	Median	95% Credible
	Mean	SD	Median	
Parameter				Interval
Age < 30				
Age 30 – 39				
Age 40 – 49				
Age 50 – 59				
Age 60 – 69	1			
Age 70 – 79				
Age 80+				
Female				
Time Bucket 1				
•••				
Time Bucket k-1				
Referent Arm	1			
Arm #2				
Arm #3				
Arm #2/Arm #3				

Graphical summaries

- 1. Stacked bar plots and cumulative distributions of HFDs by treatment arm
- 2. Stacked bar plots and cumulative distributions of HFDs by time epochs

3. Stacked bar plots and cumulative distributions of HFDs by sex

1. The Variant Secondary analysis

 The following posterior probabilities will be reported for each time epoch

Quantity of Interest	Posterior Probability
B+E superior to B	
B+E combination futile to B	
C+I superior to B	
C+I superior to B+E	

Statistical Triggers Met for Equivalence with delta ranges of equivalence

The following will be reported:

Odds-Ratio	Mean	SD	Median	95% Credible
	Mean	SD	Median	
Parameter				Interval
Age < 30				
Age 30 – 39				
Age 40 – 49				
Age 50 – 59				
Age 60 – 69	1			
Age 70 – 79				
Age 80+				
Female				
Time Bucket 1				
Time Bucket k-1				
Referent Arm	1			
	For each t	ime-epo	och	
Arm #2				
Arm #3				
Arm #2/Arm #3				

Graphical summaries

4. Stacked bar plots and cumulative distributions of HFDs by treatment arm by time epoch

References

1604 1605

1606

1607

1608

- 35. U.S. Food and Drug Administration News Release. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. 2020 November 9. Available at: https://bit.ly/2HesBBs. Accessed July 20, 2021.
- 36. U.S. Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab. Available at: https://www.fda.gov/media/143603/download. Accessed July 20, 2021.
- 37. U.S. Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. Available at: https://www.fda.gov/media/145802/download. Accessed July 20, 2021.
- 38. U.S. Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of REGEN-COVTM. Available at: https://www.regeneron.com/downloads/treatment-covid19-eua-fact-sheet-for-hcp.pdf. Accessed July 20, 2021.
- 39. Angus D. Fusing Randomized trials with big data: the key to self-learning health care systems? JAMA 2015;314:767-8.
- 40. U.S. Department of Health & Human Services. Monoclonal Antibodies: Updates from the Federal COVID Response. 2021 June 15. Available at https://leadingage.org/sites/default/files/ASPR_%20AHCA_AMDA_LeadingAge%20Monoclonal%20Webinar_20210615.pdf. Accessed July 20, 2021.

Standard CONSORT with Pragmatic Trials Checklist

Section	Item	Standard CONSORT Description	Pragmatic Trials Extension	Page
Title and abstract	1	How participants were allocated to interventions (e.g., "random allocation," "randomized," or "randomly assigned")		1-4
Introduction				
Background	2	Scientific background and explanation of rationale	Describe the health or health service problem that the intervention is intended to address and other interventions that may commonly be aimed at this problem	5
Methods				
Participants	3	Eligibility criteria for participants; settings and locations where the data were collected	Eligibility criteria should be explicitly framed to show the degree to which they include typical participants and/or, where applicable, typical providers (e.g., nurses), institutions (e.g., hospitals), communities (or localities e.g., towns) and settings of care (e.g., different healthcare financing systems)	7-8
Interventions	4	Precise details of the interventions intended for each group and how and when they were actually administered	Describe extra resources added to (or resources removed from) usual settings in order to implement intervention. Indicate if efforts were made to standardize the intervention or if the intervention and its delivery were allowed to vary between participants, practitioners, or study sites Describe the comparator in	_
	_		similar detail to the intervention	
Objectives	5	Specific objectives and hypotheses		5
Outcomes	6	Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors)	Explain why the chosen outcomes and, when relevant, the length of follow-up is considered important to those who will use the results of the trial	8
Sample size	7	How sample size was determined; explanation of any interim analyses and stopping rules when applicable	If calculated using the smallest difference considered important by the target decision maker	

Section	Item	Standard CONSORT Description	Pragmatic Trials Extension	Page
			audience (the minimally important difference) then report where this difference was obtained	
Randomization— sequence generation	8	Method used to generate the random allocation sequence, including details of any restriction (e.g., blocking, stratification)		
Randomization— allocation concealment	9	Method used to implement the random allocation sequence (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned		6
Randomization— implementation	10	Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups		
Blinding (masking)	11	Whether participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment	If blinding was not done, or was not possible, explain why	9
Statistical methods	12	Statistical methods used to compare groups for primary outcomes; methods for additional analyses, such as subgroup analyses and adjusted analyses		9-11
Results				
Participant flow	13	Flow of participants through each stage (a diagram is strongly recommended)—specifically, for each group, report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome; describe deviations from planned study protocol, together with reasons	The number of participants or units approached to take part in the trial, the number which were eligible, and reasons for non-participation should be reported	12
Recruitment	14	Dates defining the periods of recruitment and follow-up		
Baseline data	15	Baseline demographic and clinical characteristics of each group		12
Numbers analyzed	16	Number of participants (denominator) in each group included in each analysis and whether analysis was by "intention-to-treat"; state the results in absolute numbers when feasible (e.g., 10/20, not 50%)		11
Outcomes and estimation	17	For each primary and secondary outcome, a summary of results for each		13

Section	Item	Standard CONSORT Description	Pragmatic Trials Extension	Page
		group and the estimated effect size and its precision (e.g., 95% CI)		
Ancillary analyses	18	Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating which are prespecified and which are exploratory		13
Adverse events	19	All-important adverse events or side effects in each intervention group		13
Discussion				
Interpretation	20	Interpretation of the results, considering study hypotheses, sources of potential bias or imprecision, and the dangers associated with multiplicity of analyses and outcomes		14-16
Generalizability	21	Generalizability (external validity) of the trial findings	Describe key aspects of the setting which determined the trial results. Discuss possible differences in other settings where clinical traditions, health service organization, staffing, or resources may vary from those of the trial	16
Overall evidence	22	General interpretation of the results in the context of current evidence		17